Identifying and treating foot ulcers in patients with diabetes: saving feet, legs and lives
This document was supported by an unconditional funding from xxxxx

Suggested citation for this document...

Editor: Rachel Webb
Project Manager and Chief Sub Editor: Camila Fronzo
Medical Writer: Jerry Hutchinson
Designer: Alison Coombes
Managing Director: Anthony Kerr (anthony.kerr@markallengroup.com)
Published by: MA Healthcare Ltd, St Jude’s Church, Dulwich Road, London, SE24 0PB, UK
Tel: +44 (0)20 7738 5454 Web: www.markallengroup.com

© JWC 2018

All rights reserved. No reproduction, transmission or copying of this publication is allowed without written permission. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of MA Healthcare Ltd or in accordance with the relevant copyright legislation.

Although the editor and MA Healthcare Ltd have taken great care to ensure accuracy, MA Healthcare Ltd will not be liable for any errors of omission or inaccuracies in this publication.

Published by MA Healthcare Ltd.
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contents</td>
<td>3</td>
</tr>
<tr>
<td>Foreword</td>
<td>4</td>
</tr>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Prevalence</td>
<td>5</td>
</tr>
<tr>
<td>Issues around misdiagnosis</td>
<td>5</td>
</tr>
<tr>
<td>Cost of misdiagnosis</td>
<td>6</td>
</tr>
<tr>
<td>Differentiation between DFUs and PUs</td>
<td>7</td>
</tr>
<tr>
<td>Causes of PUs and DFUs</td>
<td>8</td>
</tr>
<tr>
<td>Assessment, referral and the multidisciplinary team</td>
<td>11</td>
</tr>
<tr>
<td>Assessment of diabetic peripheral neuropathy</td>
<td>11</td>
</tr>
<tr>
<td>Vascular status assessment</td>
<td>13</td>
</tr>
<tr>
<td>Patient assessment</td>
<td>15</td>
</tr>
<tr>
<td>PU grading systems</td>
<td>17</td>
</tr>
<tr>
<td>DFU grading systems</td>
<td>19</td>
</tr>
<tr>
<td>Risk assessment</td>
<td>20</td>
</tr>
<tr>
<td>Pressure ulcer risk assessment</td>
<td>20</td>
</tr>
<tr>
<td>DFU risk assessment</td>
<td>21</td>
</tr>
<tr>
<td>Referral</td>
<td>21</td>
</tr>
<tr>
<td>Emergent referral</td>
<td>22</td>
</tr>
<tr>
<td>Prevention, management and treatment strategies</td>
<td>26</td>
</tr>
<tr>
<td>Pressure reduction, redistribution and removal</td>
<td>26</td>
</tr>
<tr>
<td>Friction and shear reduction</td>
<td>27</td>
</tr>
<tr>
<td>Skin care</td>
<td>27</td>
</tr>
<tr>
<td>Nutrition</td>
<td>27</td>
</tr>
<tr>
<td>Wound management</td>
<td>30</td>
</tr>
<tr>
<td>General principals of wound management</td>
<td>30</td>
</tr>
<tr>
<td>Care plans</td>
<td>31</td>
</tr>
<tr>
<td>Managing the underlying condition and causes: PU</td>
<td>31</td>
</tr>
<tr>
<td>Management of exudate</td>
<td>33</td>
</tr>
<tr>
<td>Management of bioburden, biofilm</td>
<td>33</td>
</tr>
<tr>
<td>and infection</td>
<td>33</td>
</tr>
<tr>
<td>Debridement</td>
<td>36</td>
</tr>
<tr>
<td>Nutrition and hydration, glycaemic control</td>
<td>37</td>
</tr>
<tr>
<td>Monitor progress and adjust care plan</td>
<td>37</td>
</tr>
<tr>
<td>Advanced technologies and alternative therapies</td>
<td>38</td>
</tr>
<tr>
<td>Education</td>
<td>42</td>
</tr>
<tr>
<td>Empower patients, families and carers</td>
<td>42</td>
</tr>
<tr>
<td>Delivery</td>
<td>43</td>
</tr>
<tr>
<td>Societal</td>
<td>44</td>
</tr>
<tr>
<td>Future research</td>
<td>45</td>
</tr>
<tr>
<td>References</td>
<td>46</td>
</tr>
<tr>
<td>Who to ask in your institution</td>
<td>47</td>
</tr>
</tbody>
</table>
Foreword
Introduction

In developed countries it has been estimated that the incidence of non-healing wounds overall is approximately 1–2% (Gottrup 2004) NEW REF.1 Pressure ulcers (PUs) and diabetic foot ulcers (DFUs) are among the most prevalent chronic wounds in many countries (Phillips and Doverl 2004; Piaggesi 2004).2,3 They are a major global clinical and health economic challenge which is expected to escalate as the population increases, poor lifestyle leads to increased diabetes and obesity, and the population ages (International Diabetes Federation 2017. Diabetes Atlas; Klepstra 2012; Sen et al 2009).4,5 International expert consensus guidelines recommend, in general terms, similar pathways for the prevention and management of PUs and DFUs (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance; Bus et al 2015).6,7 Nevertheless, critical differences in the precise delivery of effective care lie within the guidelines which, if not administered appropriately to the diagnosis, are likely to lead, at best, to slow healing. PUs and DFUs, despite describing clinically different indications, share commonalities in definition, for example shear and friction, pressure, and ischaemia (Vowden P, Vowden K 2016).8 However, they require quite different approaches to management. These differences can lead to patients being managed on the wrong pathway. This consensus paper addresses these similarities and differences with two key objectives. First, to differentiate between PUs and DFUs with regard to their definition, causes, assessment, diagnosis, management and treatment, and secondly to address confusion and lack of evidence when differentiating PUs and DFUs. An example is how to manage a patient with diabetes who also has a PU.

Prevalence

Approximately 451 million adults worldwide have diabetes, a figure projected to increase to 693 million by 2045 globally (International Diabetes Federation 2017).4 The prevalence of DFUs will also increase in line with this. The lifetime incidence of DFUs is reported to be 25% (Armstrong Boulton Bus in NEJM in 2017)9 and the global prevalence of DFUs in patients with diabetes is 6.3% (Zhang et al 2017)10 with wide variation by country (Coleman et al 2013; Gottrup et al 2013; Graves et al 2014; Karayurt et al 2016; Moore et al 2015). When PUs occur on the foot, those on the heel are the most common (VanGilder et al 2008; Vowden KR, Vowden P 2009); the overall PU prevalence in five European countries is 18.3%, (VanGilder et al 2008) while over 2.5 million people in the US develop a PU annually (AHRQ), where the prevalence across all settings is 12.3% (VanGilder et al 2008). More recent figures suggest the prevalence of PUs in Canada is 26% (Pressure Ulcer Prevention – Ontario Health Technology Assessment Series 2009; Norton et al 2018) and in Western Australia between 6.3% and 9.5% (Nguyen et al 2015).

Issues around misdiagnosis

Differentiating between a heel wound that is a PU rather than a DFU presents a diagnostic challenge for clinicians. Furthermore, the prognosis, complications and treatment pathways/responsibility of care for PUs and DFUs are different. Risk factors for PUs include diabetes and perfusion (Carlsson & Gunningberg 2017; Doupe et al 2016; Lumbely et al 2014), which should be considered in the formation of PU guidelines (Bakker et al 2012; Morbach et al 2014; Lavery et al 2016; National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance). Pressure is a common factor in the formation of both a PU on the foot and DFU, and both are managed in fundamentally the same way by reducing or redistributing the pressure (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance; NICE Guideline Diabetic foot problems: prevention and management. NG19). However, care pathways for PUs and DFUs are different, reflecting the specific characteristics of the wounds and skill sets required. It is critical to understand the patient clearly, to make an accurate diagnosis and to implement the management strategy appropriate to
the wound, particularly where overlap in definitions exists (Vowden P, Vowden K 2016). Among nurses caring for DFUs, around 35% may have only minimal knowledge of the diabetic foot (Edwards et al 2005). Furthermore, PUs and DFUs on the heel may be diagnosed differently depending on the specialism of the health professional, leading to inappropriate care particularly in the community setting (Ousey et al 2011; Vowden P, Vowden K. 2016). In countries such as the US, where payment for care depends on the identity assigned to the wound, the correct diagnosis may make the difference between receiving, or not, certain types of management and products. (Mathauer, I, Wittenbecher, F. Mihailovic N, Kocic S, Jakovljevic M). For example, Apligraf for PU treatment is not even mentioned for reimbursement in the US. http://www.apligraf.com/professional/pdf/Cigna.pdf.

Cost of misdiagnosis
Incorrect diagnosis leading to an inappropriate care pathway will lead to financial and patient-related cost. Management of PUs in all health-care systems is costly (Chan et al 2017; Dealey et al 2012; Dreyfus et al 2017; Guest et al 2017; White et al 2017) and associated with higher mortality (Bauer et al 2016, Pokorna, 2017). Complications in the diabetic foot are among the most serious and costly in patients with diabetes. A third of the total cost of managing diabetes is attributable to DFUs, and these are significantly higher after ulceration compared with patients with diabetes and no foot ulcers (Driver et al 2010). DFUs, and if not successfully treated the resulting amputations, often involve lengthy stays in hospital (McInnes 2012). The cost of a DFU is high in all health-care systems (Chan et al 2017; Prompers et al 2008; Rinkel et al 2017) and increases with severity. DFUs are widely recognised to have a major impact on patients’ quality of life (QoL) (Brod 1998; White 2011) and impact the wider family and friends. QoL is also adversely affected by PUs and any misdiagnosis is likely to exacerbate this.

It is clear that the costs of both PUs and DFUs are high, and escalate with severity. Ensuring that the correct diagnosis is made and care pathway, designed by appropriately-qualified and experienced health professionals, is followed will help in controlling the already patient-related and health-care-related costs of PUs and DFUs, and provide the greatest probability of success in healing the ulcer and avoiding complications.

This is a working document that addresses general principles and provides guidance intended to minimise the likelihood of misdiagnosis and inappropriate management of PUs and DFUs. It should be read and implemented in conjunction with the clinician’s local guidelines. It brings theory and practice together, and offers areas of reflection that allow the reader to review the information and then decide where and how to use it to underpin their own clinical area. The consensus will inform and enable opportunities for practice change.
Diabetic foot ulcers (DFUs) and pressure ulcers (PUs) have been defined in detail by a number of expert panels, consensus documents and publications (IWGDF Consensus pathophysiology of foot ulceration; National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance; Bus et al 2015; Vowden & Vowden 2016). According to the International Working Group on the Diabetic Foot (IWGDF Consensus pathophysiology of foot ulceration) a DFU is defined as:

‘A full-thickness wound below the ankle in a diabetic patient, irrespective of duration. Skin necrosis and gangrene are also included in the current system as ulcers.’

The key elements are the location of the wound and the diagnosis of diabetes. The breadth of this definition means that a PU on the foot in a patient with diabetes is a DFU, as would be any foot wound in a patient with diabetes (Vowden & Vowden 2016). A DFU can occur on any part of the foot including the plantar and dorsal surfaces. A DFU may be neuropathic, ischaemic or a combination of these two factors known as neuroischaemic, but the three types of DFUs have overlapping pathophysiology (IWGDF Consensus pathophysiology of foot ulceration).

A PU is defined by the European Pressure Ulcer Advisory Panel (EPUAP), National Pressure Ulcer Advisory Panel (NPUAP), and Pan Pacific Pressure Injury Alliance (PPPIA) (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance) as:

‘A localised injury to the skin and or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear.’

The scope of this definition encompasses skin and tissue damage that results from pressure and/or shear and friction, irrespective of comorbidities. Nevertheless, there is scope for imprecision in the diagnosis and definition of a PU. The EPUAP definition warns us that:

‘A number of contributing or confounding factors are also associated with PUs; the significance of these factors is yet to be elucidated.’

This implies that merely diagnosing a wound as a PU does not necessarily fully describe the ulcer and therefore the care that it should receive. The definition of PU also encompasses those that occur at the end of life, related to Skin Changes at Life’s End (SCALE) or Kennedy Terminal Ulcers (Kennedy 1989; Shank 2009), and PUs that are caused by medical devices used appropriately or inappropriately. These include PUs that result from the use of respirator masks, intubation, catheters, splints, casts, and compression bandaging (Vowden & Vowden 2016, Pokorna 2016).

Where heel PUs and DFUs are concerned, there is clear room for overlap in their definitions if not their precise underlying causes. The consensus panel recognises, in addition to other diagnostic features, that the degree of patient mobility could be a defining characteristic. PUs tend to be associated with immobility; DFUs tend to be associated with
mobility. This is not an absolute differentiator. Where a heel PU is related to friction and shear, the patient may have been able to move in order to cause friction. This may be deliberate movement, where the patient tries to reposition themselves pushing with their heels. However, movement may be passive where the patient is moved manually by health professionals as part of care. For example, passive friction and shear may be caused by articulating bed frames, used widely in EU hospitals to assist in patient handling while reducing risk of injury to staff. Involuntary sliding movement of the heel up to 15 or 20cm, which is recognised as a risk for heel injury, occurs when these bed frames are articulated (Fletcher 2015). On the other hand, mobility is more prominent in the development of a DFU, where repeated friction and pressure on the foot, as the result of patient walking (ambulating), can cause the trauma component of ulceration.

From the viewpoint of management of the wound and the patient on the appropriate pathway, the critical factor is accurate assessment and diagnosis rather than the precise terminology used. Guidelines followed to achieve accurate assessment may be expert consensus guidelines, but they should be used in conjunction with local or national guidelines. The name ascribed to the ulcer is a start point; the factors that underlie the ulcer are the targets for management and must be clearly identified to develop an effective care plan.

**Causes of PUs and DFUs**

The pathophysiology of a DFU is complex and multifactorial (Fig 1). A patient with Type 1 or Type 2 diabetes may develop a number of underlying comorbidities that lead to an at-risk foot. At this stage the foot does not have an active DFU but is at high risk of forming one. Key factors in the risk of development of DFUs include (IWGDF Guidance on the prevention of foot ulcers in at-risk patients with diabetes. 2015; Boulton 2013):

- Peripheral neuropathy, which reduces the ability to sense touch and pain and causes loss of protective sensation
- Foot deformity as a result of damage to the distal nervous system, that leads to small muscle wasting and muscle atrophy. The deformed foot (sometimes referred to as a Charcot deformity) is subject to increased pressure where bony prominences become more pronounced and the protective fat pads under the heels and metatarsal heads shifts, exacerbating the harmful effects of pressure
- Autonomic neuropathy, causing loss of sweating that leads to dry skin and callus formation which increases pressure locally, and increases the likelihood of the skin cracking. Autonomic neuropathy also causes increased peripheral blood flow and distended foot veins and a warm, dry foot. This can appear to be a healthy foot when, in fact, it is at risk
Peripheral arterial disease (PAD) is present in nearly half of patients with diabetes (Prompers et al 2007) leading to reduced blood supply and tissue ischaemia. PAD is more common in Type 2 diabetics than in Type 1 (McAlpine et al 2005).

A history of previous DFU or amputation.

Older patients who have had diabetes for longer and male patients are at higher risk of DFU formation. When one or more of these underlying causes are overlaid with pressure and trauma from footwear or other sources, skin damage can lead to ulceration (Reiber et al 1999). Infection is not regarded as a cause of DFUs, but a consequence of a DFU (Boulton 2013).

Amputation in the diabetic foot is preceded by a DFU in approximately 80% of cases (Boulton 2013).

The pathway to PU formation comprises three well-documented key factors: pressure, friction and shear, and moisture (Fig 1). Immobility is a fourth component. Patients may be bed-bound with comorbidities, be elderly with end-stage conditions, be immobile from spinal cord injury or during surgery. Moisture alone will not lead to PU formation (NPUAP etc) but in combination with pressure, and/or friction and shear, is associated with ulcer formation. Shear is recognised by the NPUAP as a primary cause of PUs (Brienza 2015). Moisture increases friction between the skin and a surface, such as a bed sheet (Gefen 2001), which causes tissue deformation when the different layers of skin move tangentially relative to each other as the patient moves. These forces may damage tissue directly (Reger et al 2010) or cause injury to superficial skin structures when a patient moves on a bed surface (Dealey et al 2015). Friction and shear predict the development of PUs in adult, critical care patients (Cox 2011). Tissue shear forces may cause cell damage and death more rapidly, over a period of minutes, than pressure alone (Gefen & Weihs 2016). Pressure over bony prominences in an immobile patient directly damages deep tissue by compression and restriction of blood flow leading to tissue death and ulceration. In contrast to shear forces, pressure acts over longer time periods, measured in hours (Gefen, 2013). Pressure over bony prominences may be three to five times higher than other tissues, and this is doubled by shear forces (Ohura et al 2008; Orsted et al 2010). Pressure over bony prominences...
Risk factors for the development of heel PUs (Black 2004) include a previous or current heel PU indicating reduced tissue tolerance; diabetes and peripheral neuropathy; stroke or cerebrovascular accident (CVA), restricting the patient’s ability to move; paralysis; hip fracture and dragging injuries from knee replacements; dementia and cognitive impairment; PVD reducing tolerance to mechanical forces; leg spasms, Parkinson’s disease or tremors causing heel rubbing; agitated heels; leg oedema, which may compromise capillary flow and reduce tissue tolerance; and frequent sliding on the bed or chair causing rubbing. Diabetes is a risk factor for PU formation, or is diagnosed in patients who develop PUs on other anatomic locations, in patients undergoing surgical procedures longer than 2 hours (Lumbeley et al 2014), patients admitted to nursing homes after transfer from hospital compared with transfer from the community, (Doupe et al 2016) patients at the end of life (Carlsson & Gunningberg 2017) and the use of medical devices is also a recognised risk for PU formation (Barakat-Johnson et al 2017; Beldon 2008; Clay et al 2018).

Summary

Between a PU on the heel and a DFU there are similarities as well as important differences (Vowden & Vowden 2016). The risk and causative factors coincide in several areas including pressure, shear forces, and peripheral blood supply. Furthermore, heel PUs and DFUs may appear similar on clinical examination and assessment. A difference in causation is immobility/mobility. A patient with diabetes and a heel ulcer may not be recognised as such and the ulcer, clinically a DFU, may be confused with a non-diabetic heel PU if the correct assessment is not conducted.

Differentiation between DFU and PU
Correct assessment of the patient to identify the ulcer aetiology, independent of the terminology used to describe it, is critical to allocating the patient to the correct care pathway. An ulcer on the heel may be described as a PU, but if the patient has diabetes the ulcer must be assessed as a DFU. This ensures that not only is the wound itself treated effectively, but the underlying causes are clearly identified and managed, and the correct guidance is given to the patient and their carer(s)/family. For example, a heel ulcer in a patient with diabetes, if managed as a PU rather than a DFU, is highly unlikely to receive the required MDT approach which is recommenced for a DFU, and is at risk of complications, deterioration and amputation, all of which could have been avoided if the correct care pathway was followed.

Having identified the condition, the next step is referral to the health professional and/or team that is best qualified to manage the patient. The outcome of the assessment identifies the key clinical and patient characteristics to be managed, and indicates the skill sets required to address them. In the case of a DFU, referral to a multidisciplinary team (MDT) is the optimal pathway.

When a patient presents with a heel ulcer, the first step should be to exclude the possibility of diabetes and that the ulcer is a DFU rather than a PU (Vowden & Vowden 2016). This step may need to be taken in the absence of information from the patient’s notes, but if available, the notes should be consulted. Where no diagnosis of diabetes has been made, two clinical signs that differentiate between a PU and a DFU should be evaluated:

- Presence of diabetic peripheral neuropathy (DPN) leading to loss of protective sensation
- Reduced arterial blood supply (ischaemia).

Furthermore, mobility/immobility can help differentiate between a DFU and PU. If any of these signs (DPN, ischaemia, mobility) are present, then the patient should be directed to the DFU care pathway for further assessment. If these signs do not suggest that the patient has a DFU, then the patient may follow the PU pathway. The following section provides guidance on conducting simple tests that require minimal equipment to identify the presence or absence of DPN and reduced blood supply in the patient’s feet, and to assess mobility.

Before any assessment of the ulcer itself is conducted, the patient history should be taken according to local practice. See page X for further details.

**Assessment of diabetic peripheral neuropathy**

Several tests are available for assessing the presence and severity of DPN. Diagnosis of DPN is made by determining presence or absence of sensation in the foot. The equipment required to conduct the tests varies between the simple and the highly complex where access to power supplies is required.
Toe Touch Test. The simplest test, which requires no specialist equipment, is a touch test, the Ipswich Touch Test (IpTT) (Rayman et al 2011; Sharma et al 2014). The sensitivity (78.3%) and specificity (93.9%) of the test are high. This test, also known as the Toe Touch Test, is always at hand, simple to conduct, safe to do, quick and easy to perform, and easily learned. It can be administered effectively by family and non-specialist carers after training.

The test is conducted by lightly touching the tips of the first, third and fifth toes and the dorsum of the hallux of both feet with the index finger, and noting whether the patient can feel or sense the touch. It is important that the index finger touch is light, without pushing, prodding, tapping or poking, to avoid the patient feeling the test by sensing movement or force. In order to ensure that the patient is unaware of the point of touch, he or she should be blindfolded or shielded from viewing the test. If the patient cannot feel the touch on two or more sites out of eight, then a diagnosis of reduced sensation is made. If the test indicates potential DPN then, where available, the patient should be referred for monofilament testing.

Nylon monofilament test. The next simplest test uses a monofilament nylon fibre, the Semmes-Weinstein monofilament, which bends or buckles when subjected to a force of 10g when pressed against a surface (Singh et al 2005). Different versions of the equipment to conduct this test are available. The simplest is a short moulded plastic handle with the monofilament attached perpendicularly at one end. Other versions comprise a reusable handle with replaceable monofilaments.

The patient is introduced to the sensation by touching an area such as the hand or inside of the wrist. The monofilament is then applied to the tips and metatarsal heads of the first, third, and fifth toes (Singh et al 2005) or the tips of the toes and the halluces (Dros et al 2009). The test should be conducted in such a way that the patient cannot see when the monofilament is applied to the skin to ensure fidelity of the test. The monofilament is applied to the skin in a non-rhythmic pattern to rule out the possibility of the patient predicting when the test is being done. The patient should indicate if they can sense the monofilament. If the monofilament cannot be felt on any one site abnormal sensation in the foot has been detected. However, sensitivity increases when up to four plantar sites are tested (Singh et al 2005). Each monofilament must be rested for 24 hours after 10 applications (Booth & Young 2000; Singh et al 2005) and replaced when bent or dependent on the manufacturer after 70–90 applications to ensure that the filament has not weakened (Lavery et al 2012) reducing the force at which it bends. It should be noted that different monofilaments perform differently (Booth & Young 2000). Those that meet the requirement for buckling at 10g force should be used. In busy clinics it may be necessary to have more than one monofilament.
available to account for the need to rest the device. A further test based on the principle of the Semmes-Weinstein hair is the von Frey’s hairs test, which enables the practitioner to determine the threshold of touch sensation by using hairs that buckle at different forces.

**Vibration perception threshold (VPT).** The simplest-to-use vibration-related device for assessing loss of sensation is a tuning fork with a specific frequency of vibration, 128 Hz. In one version of the test (Canadian Diabetes Assoc 2013), the tuning fork is set vibrating by striking it on the palm of the hand lasting 40 seconds. As with the monofilament test, it is then applied to the hand or wrist. The test on the foot is conducted on the dorsal surface of the great toe on the bony prominence just proximal to the nail bed. The patient indicates whether the vibration is sensed and then again when the vibration has decayed and stopped. The test is repeated on the same foot and other foot in a non-predictable sequence.

An alternative to the tuning fork method is a small, battery-powered, hand-held device, the VibraTip (Bowling et al 2012). This device has been reviewed by the UK National Health Service body that develops guidance on new medical device technologies, the Medical Technologies Advisory Committee (MTAC), and is recommended for identifying peripheral neuropathy in the diabetic foot NICE MTG22). It is used in the same way as the tuning fork.

**Other methods to determine diabetic peripheral neuropathy.** Other simple manual and complex electromechanical devices are available to identify DPN (Yang et al 2014). Manual devices include the tactile circumferential discriminator which detects the ability of the patient to discriminate two points applied close together on the skin and a test that uses ball bearings of increasing diameters to identify the smallest one that the patient can feel. A number of electromechanical devices are available to measure VPT. Examples are Biothesiometer, Neurothesiometer, Maxivibrometer, Vibrameter, Vibratron and the CASE IV system (Yang et al 2014). These require access to power and may be unsuitable for use in many locations.

**Ankle reflexes.** Absence of ankle reflexes is associated with an increased risk of foot ulcer formation in patients with diabetes (Boulton et al 2008). The test requires a tendon hammer which is used to strike the Achilles tendon, the health professional performing the test would dorsiflex the foot to put the tendon on stretch before striking with a hammer. Absence of a reflex is abnormal and indicates the need for further assessment.

**Vascular status assessment**

Several tests are available for assessing the presence and severity of reduced blood supply that indicates possible ischaemia. Initial assessment may be done using simple tests that require no or minimal equipment, or by equipment of increasing complexity and greater discriminatory potential. In order to ensure that the patient is directed to the optimal care pathway it is necessary to conduct only simple tests. Where vascular issues and reduced blood supply are suspected the patient should be referred for specialist vascular assessment. Simple tests that require no or minimal equipment include:

**Pulse palpation.** (Blume & Wu 2018; Earnshaw 2003; Lewis & Owens 2010). Where other methods of identifying vascular issues and ischaemia are not available, palpation of dorsal pedal pulses allows initial screening and requires no equipment. In this test the practitioner assesses the pulse in the posterior and anterior tibial arteries by palpation. The posterior tibial pulse is palpated just behind the medial malleolus. The anterior tibial pulse should be palpated at the ankle, at the midpoint between the two malleoli not more distally in the foot, where it lies deeper. If there is any doubt about the presence of a pulse, use the Doppler. (Earnshaw JJ, 2003) The dorsal most prominence of the navicular bone is marked. Pulse palpation is evaluated by using two fingers, the index and middle fingers of the dominant hand. Attempted detection of the pulse is initiated at the dorsal most
prominence of the navicular bone and carried out following an arc over the dorsum of the foot towards the lateral malleolus in a posterior-lateral direction.

Note: a diabetic foot with neuropathy and no ischaemia may present as warm and with bounding pulses (Boulton et al 2008). In this case, do not rely only on pulse palpation for differentiating a PU and a DFU but use all assessment outcomes as a set to inform the decision. Furthermore, peripheral vascular arterial (PAD) can still be present despite the presence of a palpable pulse.

Ankle-brachial pressure index (ABPI). ABPI involves the ratio of systolic pressures in the brachial artery at each elbow and systolic pressures in the posterior tibial and dorsalis pedis arteries at each ankle. ABPI is calculated for each leg separately. The American Heart Association (AHA) for example recommends that the higher of the two ankle systolic arterial pressures (termed high ankle pressure) be used as the numerator in the ABPI equation. Others recommend that the lower of the two ankle systolic pressures (termed low ankle pressure) be used as the numerator when calculating ABPI. Some use an average of the two ankle systolic pressures as the numerator while others default to using the posterior tibial artery systolic pressure to calculate ABPI. Suggested delete by reviewer as confusing Will delete unless any objections

ABPI is conducted with the patient in the supine position (lying down). Evidence states that 10 minutes of supine rest as a minimum before pressure measurement is recommended (Sadler, Chuter) to allow equaling vascular beds which determine arterial pressure. The sphygmomanometer cuff is placed around the ankle above the malleoli. The location may vary slightly from anywhere from just above the malleoli to 2.5cm above the malleoli, depending on which guidelines are followed. Where the ABPI is recorded ≤0.9 (Aboyans) the patient should be referred for further specialist vascular assessment using more sensitive methods.

Patients with diabetes may have hardening of the arteries, and medial arterial calcification (MAC) in the lower leg and foot which reduces the compressibility of the arteries. The presence of MAC is known to reduce the compressibility of the vessel and can lead to false elevation of the ABPI. This makes ABPI interpretation in diabetes populations difficult. Clinicians should be aware that the ABPI should not be used as a stand-alone screening tool in diabetic populations, but in conjunction with other testing methods. Clinicians should consider using other non-invasive vascular tools such as hand-held Doppler to use alongside ABPI to assist with accurate identification of PAD. Where the ABPI is measured as ≥1.3, further tests such as a TBP should be performed and if this is not possible the patient should be refer for vascular assessment.

Note: diabetes involves the medium lumen and therefore the ABPI might not be accurate and a TBI is better.

Toe-brachial Index (TBI): TBI represents an alternative diagnostic tool in patients with diabetes and PAD. Digital arteries are usually less affected by calcifications, provides insight into the microvascularity of the smaller vessels of the foot. TBI is obtained by dividing the toe systolic pressure by brachial systolic pressure. Since toe pressures are generally about 60% that of brachial pressures, prognosis is relatively good when toe systolic pressure is >40mmHg. TBI≥0.6 is considered within normal limits, TBI≤0.6 is an indication of obstruction or PAD and TBI≥1 was considered distal arteries calcification. [PANEL PLEASE CONFIRM]

Doppler ultrasound. Using a handheld Doppler, the output from a continuous wave Doppler ultrasonography is usually presented as an audible signal, so that a sound is heard whenever there is movement of blood in the vessel being examined. PAD can change the sound and shape of the noninvasive Doppler ultrasound waveforms recorded from arteries in the lower limbs. A triphasic wave form
is representative of good arterial flow. The extra sound associated with the triphasic waveform is called the dichrotic notch and represents elastic recoil of the artery. A biphasic waveform presents haemodynamically significant stenosis and a monophasic waveform represents presence of severe PAD.

The first test should be pulse palpation. Furthermore, ABPI could be false in patients with arterial calcification. If the patient does not have pulse refer, where possible, to a vascular surgeon (or relevant health professional) for a full assessment.

**Patient assessment**

In most cases the health professional who conducts the initial assessment of a patient with a heel ulcer is the ‘wound care navigator’ (WCN) (REF Managing wounds as a team). Referral to the WCN may have been made by a general practitioner or other primary care practitioner, a nurse, or the patient may have self-referred. The skill level of the WCN with respect to wound management may be high as with a podiatrist, Wound, Ostomy and Continence Nurses (WOCN) in the US, Tissue Viability Nurse (TVN) in the UK, TVN or advanced nurse practitioner in Ireland or a nurse with advanced wound care knowledge in other parts of Europe. The extent of patient management undertaken by the WCN should be in line with their skill level, with referral further through the healthcare system according to the patient’s clinical needs. Minimally, the WCN should be trained to conduct the initial steps required to assess the patient and to conduct the tests required based on the ulcer characteristics. Local or national guidelines should be consulted to ensure that optimal care is delivered. In general, the steps are:

1. **Record patient history:** including: patient characteristics, such as age and sex, relevant medical history, current medications and previous ulceration or amputation. The Health professional should specifically ask about diabetes; the patient may disclose that they have diabetes or may not know if it is undiagnosed. A family history of diabetes, especially type 2, is important. Record the duration and type of diabetes if it is known. Record the lower limb condition—hairs, temperature, colour, skin conditions, such as hyperkeratosis. Also, note how the ulcer is being managed at the point of presentation, for example, is the patient using offloading of any sort.

2. **Assess the wound characteristics:** including location (plantar, heel, metatarsal head(s), instep, dorsal, lateral), size, depth including presence of underlying function, edge and periwound appearance, exudate type, visual appearance, pain, presence of infection and surrounding cellulitis and redness, skin condition (whether it’s dry, atrophic, fissures, cracks) and temperature (a dramatic drop in skin temperature from proximal to distal along the lower limb can be a sign of poor blood flow). Assess the foot for callus and deformity, which increase local pressure, for example hammer toes, prominent metatarsal heads and Charcot deformity. Amputation should also be recorded. The nails and between the toes should be assessed for signs of fungal infection. PUs on the foot are usually on the heel.

When assessing a wound, the acronym MEASURE may be useful (REF). The acronym stands for:

- M: measure size
- E: exudate amount (none, scant, moderate, heavy) and characteristics (serous, sanguinous, pustular, or combinations)
- A: appearance, necrotic (black), fibrin (firm yellow), slough (soft yellow), or granulation tissue (pink and healthy versus red and friable—easy bleeding, unhealthy)
- S: suffering pain
- U: undermining measured in centimetres and position in the ulcer recorded
- R: re-evaluate
- E: edge (hyperkeratotic, macerated, normal).
3 Identify the degree of patient mobility: if the patient is bed-bound or relatively immobile, it is likely that the ulcer is a PU, whereas if a patient is reasonably mobile it is more likely that the ulcer is a DFU. [do you mean a mobility scale or a risk assessment scale. My advice would be to say that attention should be made to the activity and mobility elements of the risk assessment tool used in the specific practice setting, then we could include in a box a number of the risk assessment tools, so that we are not specifically recommending any one in particular.]

4 Assess DPN and/or blood supply using the test best suited to the equipment and skills available: this may be a simple test requiring no equipment, such as pulse palpation and the toe touch test.

5 Refer the patient to the appropriate care pathway based on the overall outcomes of the assessment: these pathways should be described by local guidelines. Note: if the patient identifies as diabetic this may be enough to lead to a referral, however, a full assessment will aid with referral urgency.

The panel decided that a useful guide to the key aspects required for the assessment of an ulcer on the foot is the mnemonic VIPS (Table 1 Fig 3):

- V: vascular/ischaemia
- I: infection/biofilm/inflammation
- P: pressure
- S: sensation/neuropathy

### Grading systems

**Fig 3. Assessments required to help determine the origin of the ulcer and relevant treatment pathway**

**Table 1. Foot VIPS assessment**

<table>
<thead>
<tr>
<th>V —vascular/ischaemia</th>
<th>Pulse palpation and if possible ankle-brachial pressure index (ABPI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I—infection/biofilm/inflammation</td>
<td>Visual signs, redness, swelling, slough, smell, reported pain</td>
</tr>
<tr>
<td>P—pressure</td>
<td>Is it caused by mobility (likely diabetic foot ulcer) or immobility (likely pressure ulcer)</td>
</tr>
<tr>
<td>S—sensation (neuropathy)</td>
<td>Touch the toes and if possible monofilament test</td>
</tr>
</tbody>
</table>

---

*S16 JOURNAL OF WOUND CARE ■ CONSENSUS DOCUMENT 2018*
The effective care of the ulcer depends on clear and accurate diagnosis and description of the condition. Where the skill level is appropriate management may be conducted by the WCN, or the patient may be referred to an appropriate health professional/service.

Many grading systems for PUs and DFUs have been published by expert groups or institutes. The healthcare provider may have developed local a grading system which should be used if available. Where a local or national grading system is not available, a grading system developed by expert consensus or other developer should be used. Grading systems assume a level of skill in order to recognise and differentiate the scoring parameters and must be administered by appropriately-qualified staff.

**PU grading systems**
**Box 3: Summary of diabetic foot ulcer (DFU) grading systems**

### SINBAD

<table>
<thead>
<tr>
<th>Category</th>
<th>Definition</th>
<th>Score</th>
<th>Category</th>
<th>Definition</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site</td>
<td>Forefoot</td>
<td>0</td>
<td>Bacterial infection</td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Midfoot or hind foot</td>
<td>1</td>
<td>Present</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Ischaemia</td>
<td>Pedal blood flow intact: at least one pulse palpable</td>
<td>0</td>
<td>Area</td>
<td>Ulcer &lt;1cm²</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Clinical evidence of reduced pedal blood flow</td>
<td>1</td>
<td>Ulcer ≥1cm²</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>Protective sensation intact</td>
<td>0</td>
<td>Depth</td>
<td>Confined to skin and subcutaneous tissue</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Protective sensation lost</td>
<td>1</td>
<td>Reaching muscle, tendon or deeper</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>TOTAL POSSIBLE SCORE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>6</strong></td>
</tr>
</tbody>
</table>

### University of Texas

<table>
<thead>
<tr>
<th>Grades</th>
<th>Description</th>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Pre- or post-ulcerative or healed wound</td>
<td>A</td>
<td>No infection or ischaemia</td>
</tr>
<tr>
<td>1</td>
<td>Superficial wound not involving tendon, capsule or bone</td>
<td>B</td>
<td>Infection present</td>
</tr>
<tr>
<td>2</td>
<td>Wound penetrating to tendon or capsule</td>
<td>C</td>
<td>Ischaemia present</td>
</tr>
<tr>
<td>3</td>
<td>Wound penetrating to bone or joint</td>
<td>D</td>
<td>Infection and ischaemia present</td>
</tr>
</tbody>
</table>

### Wagner

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Intact Skin</td>
</tr>
<tr>
<td>1</td>
<td>Superficial ulcer of skin or subcutaneous tissue</td>
</tr>
<tr>
<td>2</td>
<td>Ulcers extend into tendon, bone, or capsule</td>
</tr>
<tr>
<td>3</td>
<td>Deep ulcer with osteomyelitis, or abscess</td>
</tr>
<tr>
<td>4</td>
<td>Gangrene of toes or forefoot</td>
</tr>
<tr>
<td>5</td>
<td>Midfoot or hindfoot gangrene</td>
</tr>
</tbody>
</table>

The most widely used grading system for PUs is that prepared by the NPUAP, EPUAP and PPPIA (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance 2014).

The term ‘pressure ulcer’ has recently been subject to review. The NPUAP in the US has proposed adoption of a new term, pressure injury (PI). This document continues to use the term pressure ulcer. The NPUAP, EPUAP and PPPIA grading system is based on the depth of the PU and the extent of tissue involvement,
Box 4: Description of the WiFi grading system which assess the wound, ischaemic and infection state

### WIFI Wound (W)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Ulcer</th>
<th>Gangrene</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No ulcer, ischaemic rest pain</td>
<td>No</td>
</tr>
<tr>
<td>1</td>
<td>Small shallow ulcer on distal leg or foot, no exposed bone unless limited to distal phalanx. Salvageable with simple digital amputation</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>Deeper ulcer with exposed bone, joint or tendon; generally not involving the heel; shallow heel ulcer without calcaneal involvement. Major tissue loss salvageable with multiple (≥3) digital amputations or standard transmetatarsal amputation; skin coverage</td>
<td>Limited to digits</td>
</tr>
<tr>
<td>3</td>
<td>Extensive, deep ulcer involving forefoot and/or midfoot; deep, full-thickness heel ulcer; calcaneal involvement. Extensive tissue loss salvageable only with a complex foot reconstruction or non-traditional TMA (Chopart or Lisfranc); flap coverage or complex wound management needed for large soft tissue defect</td>
<td>Extensive gangrene involving forefoot and/or midfoot; full-thickness heel necrosis &amp; calcaneal involvement</td>
</tr>
</tbody>
</table>

### WIFU Ischaemia (I)

<table>
<thead>
<tr>
<th>Grade</th>
<th>ABI</th>
<th>Ankle systolic pressure</th>
<th>TP, TcPO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>≥0.80</td>
<td>&gt;100 mmHg</td>
<td>≥60 mmHg</td>
</tr>
<tr>
<td>1</td>
<td>0.6–0.79</td>
<td>70–100 mmHg</td>
<td>40–59 mmHg</td>
</tr>
<tr>
<td>2</td>
<td>0.4–0.59</td>
<td>50–70 mmHg</td>
<td>30–39 mmHg</td>
</tr>
<tr>
<td>3</td>
<td>≤0.39</td>
<td>&lt;50 mmHg</td>
<td>&lt;30 mmHg</td>
</tr>
</tbody>
</table>

### WIFI Infection grade (FI—foot infection)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No symptoms or signs of infection</td>
</tr>
<tr>
<td>1</td>
<td>Local infection involving only skin, subcutaneous (SQ) tissue</td>
</tr>
<tr>
<td>2</td>
<td>Local infection with erythema &gt;2 cm, or involving structures deeper than skin, SQ (eg, abscess, osteomyelitis)</td>
</tr>
<tr>
<td>3</td>
<td>Local infection with signs of SIRS</td>
</tr>
</tbody>
</table>

and assigns a PU to ‘categories’ or ‘stages’ as shown in Box 2.

**DFU grading systems**

A number of grading systems for DFUs exist. The most commonly-used systems are SINBAD, Wagner, University of Texas, Wound Ischaemia and Foot Infection (WIfI) and PEDIS. In general, the grading of DFUs is based on the size of the ulcer and the presence or absence of DPN, PAD and infection although the detail of how this is achieved by each system varies. Where they exist, clinicians should use local grading systems. Where no local system is available, one of the existing systems should be adopted according to local preference.

**SINBAD** (Ince et al 2008); an acronym for site: ischaemia; neuropathy; bacterial infection; area; and depth. Each parameter is allocated a score of either ‘0’ or ’1’ according to the system shown in Box 3 and the
total score for the DFU is calculated. Higher scores indicate greater severity.

**University of Texas**: assesses the DFU on two parameters and provides an alphanumeric score that is an combination of the two as shown in Box 3.

**Wagner** (Frykberg 2002; Wagner 1981): uses six definitions that incrementally describe a DFU by the degree of severity (Box 3).

**Wound Ischaemia and Foot Infection (WIfI)** (Mills et al 2014): developed to assess patients with critical limb ischaemia. WIfI assesses the wound, ischaemia, and foot infection and assigns a score to the ulcer. The WIfI system correlates well with outcomes for wound healing and amputation (Zhan et al 2015). The scoring system is shown in the Box 4.

**PEDIS**: developed by the IWGDF to use strict criteria that are applicable worldwide (Schaper 2004). It was developed primarily for use in research (Schaper 2004) and as such is unlikely to be used widely in the management of DFU outside research.

**Risk assessment**

Risk assessment estimates the level of risk that a patient will develop a new ulcer or a recurrent ulcer and in the case of DFU progress to amputation. It is recommended that risk assessment is conducted for all patients who currently do not have an ulcer, or who have a healed ulcer in order to identify where prevention strategies should be focused. Where local guidelines are available for conducting risk assessment these should be used. Where local or national guidelines are not available there are a number of risk assessment tools or instruments that may be used.

**Pressure ulcer risk assessment**

Many risk assessment tools have been developed for PU. Examples include the Braden Scale, Waterlow, and Norton, [REFERENCES]. PU risk assessment should be a combination of a structured assessment based on a tool and clinical judgement (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance 2014). Good clinical judgement requires experiences in risk assessment and if there is any doubt at least another one person should carry out the assessment. Risk assessment should be conducted and documented as soon as possible after a patient is referred or presents, and in any case no later than 8 hours after arrival. It should be repeated especially if there is a change in the patient’s condition or if for PUs, where possible, on a daily basis if in hospital. (Pokorná, A., Leaper, D)

A number of factors are reported to increase the risk of PU formation including poor skin condition, an existing PU, immobility, poor nutritional status, higher or lower than average BMI, female sex, greater age, incontinence and increased skin moisture,

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Characteristics</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No diabetic peripheral neuropathy (DPN)</td>
<td>Once a year</td>
</tr>
<tr>
<td>1</td>
<td>DPN</td>
<td>Once every 6 months</td>
</tr>
<tr>
<td>2</td>
<td>DPN with peripheral artery disease and/or a foot deformity</td>
<td>Once every 3–6 months</td>
</tr>
<tr>
<td>3</td>
<td>DPN and a history of foot ulcer or lower-extremity amputation</td>
<td>Once every 1–3 months</td>
</tr>
</tbody>
</table>
comorbidities such as cachexia and organ failure, PAD, anaemia, motor and sensory impairment, spinal injury, and diabetes. Most risk assessment tools are based on these risk factors and assign a score to the patient which identifies the risk category for PU formation in the patient. A risk factor for heel PU in particular is a degree of mobility that allows the patient to move themselves for example on a bed, or in patients with leg spasms, Parkinson’s disease or tremors causing heel rubbing, agitated heels, and frequent rubbing by sliding on a bed or chair. Articulated bed frames can also increase risk of heel PU.

Skin inspection is a critical step in PU prevention and should be done regularly. The skin should be inspected within six hours of admission to a hospital and daily thereafter. All skin sites susceptible to PU formation should be assessed for pain or discomfort reported by the patient and the skin should be checked for:

- Skin integrity in areas of pressure
- Colour changes or discolouration. Non-blanchable erythema may present as colour changes or discolouration, particularly in darker skin tones or types
- Variations in heat, firmness and moisture (for example, because of incontinence, oedema, dry or inflamed skin).

Use finger palpation to determine whether erythema or discolouration (identified by skin assessment) is blanchable. A simple test to assess redness is to place a transparent plastic disc over the skin as it is depressed. Blanchable redness is identified by the skin losing redness which returns when the pressure is released and blood perfusion returns. Non-blanchable redness does not lose its red colouration and indicates development of inflammation in the skin. Where available diascopy may be used to evaluate skin (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance 2014; NICE 2017 PU prevention).

Developments in skin assessment include new methods to assess pathological change in at-risk skin. Where skin changes that may lead to PU formation have started the tissue becomes inflamed. Early inflammatory changes include extravascular fluid accumulation in the matrix of skin which are not visible to the naked eye. This fluid is called sub-epidermal moisture (SEM). The assessment method measures an electrical property of skin, impedance, which changes with SEM (Bates-Jensen et al 2017; Moore et al 2017). A device to measure SEM is commercially available and offers advantages in detection of potentially damaging skin changes up to five days before they are visible to the eye. Where available the use of this device should be considered.

DFU risk assessment
All patients diagnosed with diabetes who develop peripheral neuropathy are at risk of DFU formation and should be managed according to local, national or international guidelines. The IWGDF has issued guidance on prevention of DFU based on assessing risk posed by DPN, foot deformity, PAD and history of foot ulceration. The associated screening frequency is recommended (Table 2). Risk assessment for progression of ulceration to amputation is covered by the WIfI assessment tool.

Every patient with diabetes and a ulcer should have a nurse or health specialist perform a simple assessment in order to determine if a vascular assessment is required. For example, if a nurse was able to get pulse palpation, that should be enough to rule out the possibility of an ischaemic condition, however if the wound fails to heal or there is any doubt the patient should be referred for further non-invasive testing e.g. toe pressures and ABPI.

Referral
Following assessment and identification of the most likely type of ulcer, the patient should be referred as early as possible to the appropriate care pathway. It is important that the correct clinical procedures and competencies are brought to bear on the wound.
Often those will not necessarily reside in a specific health professional. The pathway that provides the optimal care, irrespective of the person who delivers the care, should be followed.

Procedures and competencies potentially required for a PU are wound care, infection management, nutrition management, debridement, pressure relief, friction and shear management, medicines, and surgery.

In the case of a DFU, the guidelines recommend referral to a multidisciplinary team (MDT) in order to manage the complexity of a patient with diabetes and a wound. Patients managed by a MDT have better outcomes than those not managed in this way (2004. MOORE). Guidelines recommend that referral should take place promptly and within 24 hours of identification of a DFU (NICE 2015 DFU prevention). Evidence suggests that this rapid referral does not happen in the majority of cases (Diabetes UK national DF audit 2018; Prompers et al 2008; Quinton et al 2015). Correcting referral intervals is likely to be a major contributor to shortening the time-to-heal for a DFU and avoiding progression to amputation. Procedures and competencies in a MDT for a DFU are wound care, infection management, nutrition management, debridement, pressure relief, friction and shear management, and surgery.

Emergency referral is required when the patient suffers from a severe infection, according Infectious Diseases Society of America (IDSA) guidelines and there is a high-risk to the patients’ life. This is especially important where there is deep soft tissue infection, necrotising soft tissue infection, acute limb ischaemia and osteomyelitis with systemic signs (fever, tachycardia, tachypnea, Leucocytosis, etc).

The multidisciplinary team

A MDT, which may also be known as an interdisciplinary team, is a group of specialists with all the skill sets appropriate to the management of a specified condition. An example is a surgical team comprising theatre staff, nursing, anaesthesiology, surgeons, ICU practitioners and so on. The critical point is that whatever structure is in place the patient should receive the best multidisciplinary care of the wound. A characteristic of a MDT is effective communication to ensure delivery of integrated care to the patient. Patients managed by a MDT tend to have better outcomes than those not managed under a MDT (Moore et al 2014). The constitution of a MDT varies worldwide (Moore et al 2014; Buggy & Moore 2017) and generally they are associated with the acute care setting rather than the community. Nevertheless a patient in the community who meets the guidelines for management by a MDT, perhaps because of a change in status of the wound, should be referred to a MDT. In the

### Table XX. Key assessment criteria for foot ulcers

<table>
<thead>
<tr>
<th>Assessment step</th>
<th>Most likely to be DFU</th>
<th>Most likely to be PU</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>Patient self-identifies as diabetic</td>
<td>Patient self-identifies as not diabetic</td>
</tr>
<tr>
<td>Mobility</td>
<td>High/moderate mobility</td>
<td>Low mobility</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Reduced blood supply</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Foot deformity</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Previous DFU or amputation</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Pain assessment</td>
<td>None</td>
<td>Pain reported</td>
</tr>
</tbody>
</table>
Assessment, referral and the multidisciplinary team

In the case of DFU the IWGDF recommends a MDT with three levels of the following structure and skills:

- **Level 1**: general practitioner, podiatry, diabetic nurse
- **Level 2**: diabetologist, surgeon (general, orthopaedic or foot), vascular specialist, endovascular interventionist, podiatrist and diabetic nurse, in collaboration with a shoe-maker, orthotist or prosthetist
- **Level 3**: a level 2 foot centre specialised in diabetic foot care, with multiple experts from several disciplines each specialised in this area working together, and that acts as a tertiary reference centre.

The ASEAN guidelines recommend the following competencies in a DFU MDT: surgery for diabetic foot problems; diabetology; diabetes nursing; podiatry; tissue viability or wound management; specialist competencies including vascular surgery, radiology, clinical microbiology, nephrology and cardiology.

Many DFU in Europe are overseen by podiatrists who make the clinical decision to refer the patient to the full MDT. Some countries stipulate that patients are managed by physicians who make the decisions on the care plan and referrals. MDTs with responsibility for the management of any chronic or acute wound are being set up in Malaysia.

To treat patients with a diabetic foot ulcer successfully, quality parameters of the facility’s structure, treatment procedures and the patient outcome are needed. Structural quality based is on the qualifications of staff, the facilities spatial conditions as well as a minimum of equipment. The application of available guidelines and documentation systems as well as the establishment of a team approach between the facility’s staff and other experts involved (vascular surgeon, orthopaedic surgeon, radiologist, podiatrist, orthopaedic shoemaker, etc.) are the requirements of procedure’s quality. Outcome quality encloses: wound healing rate and time, rate of amputation (major and minor), vascular intervention (surgery, percutaneous transluminal angioplasty), death rate, clinical admission. In Germany a certification system was established in 2005; there is a clear link and rules for responsibility from general practitioners (GP) to diabetologist and finally specialised centres. Centres are available in all regions of Germany. A comparable System was established in Belgium.

Competencies required may also include infection control, infection management and microbiology, wound care, total contact casting (TCC), physiotherapy, occupational therapy, nutrition and patient educator. Some counties may not have practitioners with a functional title such as podiatrist. However the functional name is less important than the availability of the skills of a podiatrist. In many European countries the US and Australia podiatrists are the main practitioners who manage patients with DFU daily and who refer to the MDT, but this is not always the case. The key competencies of a podiatrist in a MDT include:

- Vascular and neuropathy assessment
- Identifying foot deformities and joint mobility range
- Foot care (calluses removal, nail care)
- Diagnosis and management of infection through prescription of antibiotics and surgical intervention, especially for osteomyelitis
- Prophylactic and conservative surgery in some countries for the correction of the deformity
- Off-loading
- Prevention of the recurrence or re ulceration through insoles and therapeutic shoes
- Surgical and sharp debridement.

PU are most often managed by nursing staff who refer to the appropriate clinical staff as required but this is not usually under the auspices of a formal MDT. In the absence of a formal MDT, PU are managed by an interdisciplinary group of practitioners. This panel recommends considering MDT for managing PU. An example of the membership is provided by the AHRQ (Agency for Healthcare Research and Quality. Preventing Pressure Ulcers).
**BOX X. Example of assessment and treatment for a diabetic foot ulcer**

<table>
<thead>
<tr>
<th>Diabetic foot ulcer at initial presentation</th>
<th>After acellular dermal matrix placement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical history</strong> Age/gender: 55 y/o male; HPI: wound started as a blister and gradually got bigger, patient hoped the wound would heal on its own; Wound duration: 8 months; Previous ulceration/amputation: No; Pain to the area: No (VAS Scale 0/10); Current wound management: self management with over the counter dressings from pharmacy; Previous medical history: type 2 diabetes (12 years), hypertension, hypercholesterolemia; Allergies: PCN, codeine; Medicines: lisinopril, atorvastatin, novolog, fuorsemide, lantis; Glycemic control: HgA1c 8.6 (6 weeks prior); Ambulatory/mobility status: able to ambulate with cane assistance and to change and control his body position</td>
<td></td>
</tr>
<tr>
<td><strong>Physical Exam Wound (VIPS)</strong> Location: left lateral heel; Size: 5.2cm x 4.3cm x 0.5cm; Base: 90% fibrotic, 10% granular; Margins: hyperkeratotic, 40% eschar noted; Tracking: none; Probing: to periosteum; Undermining: 0.8cm along dorsal border; Odour: no; Exudate: mild serosanginous exudate on dressing. No active drainage from wound; Vascular: DP/PT pulses: non palpable; DP pulse biphasic; PT pulse monophasic via doppler; ABPI: 0.9; TCPO2: 42mmHg; Infection: No periwound oedema or erythema. =No purulence. No active drainage. No fluctuance. No odour. No slough. Wound deep and probes to periosteum. Possible bone infection; Pressure: Primarily from shoegear; patient’s foot measured as size 11 but wearing size 10 shoes; Sensation: SWM 0/10; vibratory sensation: diminished; Toe Touch Test: 2/8</td>
<td></td>
</tr>
<tr>
<td><strong>Tests/Referrals</strong> Vascular: Given that patient’s pulses were non palpable and ABPI was 0.9, vascular was consulted who ordered a transcutaneous oxygen pressure to assess wound’s potential for healing; TCPO2 was 42mmHg indicating good potential to heal without need for vascular surgery; Radiographs or MRI (since the wound probed to periosteum. Radiographs and MRI ordered to rule out osteomyelitis). Both radiographs and MRI were negative for osteomyelitis; Nutritional consult; Endocrinology consult; Pedorthic consult</td>
<td></td>
</tr>
<tr>
<td><strong>Staging and Treatment</strong> Staging for DFU: Wagner’s Grade 2 ulcer; UTSA – Grade 3A; WfI – stage 2; Given that patient had no contraindications to healing, wound surgically debrided and acellular dermal matrix applied; Patient was offloaded with an instant total contact cast with extra padding around the heel. Patient healed in 10 weeks and progressed on to a well fitted diabetic shoe with custom diabetic inserts.</td>
<td></td>
</tr>
</tbody>
</table>
**BOX X. Example of assessment and treatment for a pressure ulcer**

<table>
<thead>
<tr>
<th>Medical history</th>
<th>Physical Exam Wound (VIPs)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age/gender:</strong> 75 y/o male; HPI: began in a flctena, with blood content that broke. Caregiver had hoped that the blood would be absorbed and the skin healed; Wound duration: 2 weeks; Previous ulceration/amputation: No; Pain to the area: yes (VAS Scale 3/10); Current wound management: caretaker wore a pads wrapping the heel to protect; Previous medical history: type 2 diabetes (2 years); Alzheimer’s disease, hypertension; Fall of the bed having been transported to the hospital where he was diagnosed Cranioencephalic Trauma and performed drainage of Subdural Hemorrhage</td>
<td><strong>Location:</strong> right lateral heel; Size: 5.4 cm x 4.8cm <strong>Base:</strong> 65% necrotic, 5% fibrotic, 20% granular, 10% epithelial; <strong>Margins:</strong> macerated; <strong>Tracking:</strong> none; <strong>Probing:</strong> No; <strong>Undermining:</strong> No; <strong>Odour:</strong> no <strong>Exudate:</strong> mild serosanginous exudate on dressing. <strong>DP/PT pulses:</strong> palpable; <strong>DP pulse biphasic:</strong> PT pulse biphasic via doppler; <strong>ABPI:</strong> 10; <strong>TCPO2:</strong> 60mmHg <strong>Infection:</strong> No periwound oedema / erythema. =No purulence. <strong>Pressure:</strong> Agitated for some periods but most of the time immobile. Do not collaborate on repositioning. <strong>SWM:</strong> 8/10; <strong>vibratory sensation:</strong> Normal; <strong>Toe Touch Test:</strong> 6/8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tests/Referrals</strong></th>
<th><strong>Staging and Treatment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vascular</strong></td>
<td><strong>Staging for PU: Unstageable Pressure Injury – Dark Eschar</strong></td>
</tr>
<tr>
<td>Palpable Pedis and Tibial Pulses. No edema in the limb and full pulse</td>
<td>During Hospitalization: ECG = 13 (O4 + V3 + M6); Fed orally from conventional soft hospital diet, dysphagia to liquids, does not always ingest the whole meal; Dependent during hospitalization, raise to highchair; during the day <strong>Score 11 on the Braden scale – High Risk</strong></td>
</tr>
<tr>
<td>Normal skin temperature on the feet, no color alterations. <strong>ABPI</strong> was 1.0.</td>
<td><strong>Treatment:</strong> Specific Heel Silicone multi-layered foam dressing and Fluidised Positioners to</td>
</tr>
</tbody>
</table>

**Images to be inserted**
The key to prevention of both PU and DFU is early identification of at risk patients and prompt implementation of effective targeted prevention strategies. Prevention is targeted at the risk factors and underlying conditions that make ulceration more likely. These strategies are the same for adult and neonates although some skin sites are more susceptible in neonates, for example the occipital area. It is important to note, there is no one-size-fits all solution for either PU or DFU prevention, both must be tailored to the individual patient.

Pressure ulcer prevention
The US AHRQ has published a detailed tool kit that guides health professionals in PU prevention (AHRQ). Where prevention strategies are not already implemented, or existing strategies are under review, it is recommended that the tool kit is consulted. All patients are potentially at risk of developing a PU. The purpose of a risk analysis is to identify those at highest risk and where early skin changes have taken place, and to target preventative interventions to them. The risk analysis should be conducted as soon as possible, and for inpatients no later than six hours after admission (NICE 2017 preventing PU in adults). The risk analysis will identify risk of PU formation and any areas of ulceration that already exist.

The start point is care standards as laid out in guidelines. The most widely-used are those of the EPUAP, NPUAP and PPPA (National Pressure Ulcer Advisory Panel). Others include those from NICE in the UK (NICE 2017 preventing PU adults). The UK NHS suggests following a 5-step process for prevention and treatment of PU known as the SSKIN Bundle (NHS SSKIN Bundle link) which follows the main principles of PU prevention and treatment. The acronym refers to surface that the patient is on, skin inspection conducted early, keep the patient moving, incontinence and moisture management to keep the patient clean and dry, and nutrition (diet and fluids).

Pressure reduction, redistribution and removal
For individuals at risk of a PU due to activity and mobility problems there are pressure redistribution options available, namely, continuous low pressure devices, such as high specification foam, and high tech surfaces (low air loss, alternating or air fluidised). Selection of the surface should be based on an assessment of the individual’s mobility status and general skin condition. Where there is no availability of these surfaces, consideration should be given to the frequency of repositioning, as this will need to be increased in order to protect the individual from the adverse effects of pressure and shear forces.

Mattresses may be augmented by additional pressure relieving and redistribution foam pads. Pressure reduction and redistribution may be targeted at a specific at-risk anatomy, for example the heel, by products that protect the heel in a pressure redistributing boot. Several such products are available including the Heelift Suspension Boot (DM Systems, UK; Position Health, US), Devon Boot and Heel Protector (Aria Medical), HeelMedix (Medline Industries), Repose Foot Protector (Frontier Medical), Mölnlycke DAP-600Z Fluidised Heel Protector Boot (Mölnlycke Health Care). Patients who are laying in a position where there may be compression of the common peroneal nerve (i.e. lower leg leaning against...
rails by the side of the bed, or against a wall or even the hand control panel) are prone to developing nerve palsy and foot drop. While the protective boot may help keep the limb in a more neutral position, not all facilities/regions have protective boots available. Hence health professionals should be aware of the possibility of developing foot drop and be on alert, noting the patient’s position to prevent the development of nerve palsy.

Pressure between the legs may be managed using products that fit between the legs and keep them separated for example Devon Utility Pad (Aria Medical). If pillows are used to manage pressure, care must be taken to ensure correct positioning so as not to cause undue pressure over any bony prominence. Also note, they increase body temperature and could cause higher levels of moisture on the skin. Furthermore, pillows may increase body temperature.

The tissue at risk may be targeted with pressure relieving and redistributing patches that are placed directly on the at-risk site. Examples include Aderma (Smith & Nephew), and KerraPro (Crawford Healthcare). Some dressings specifically designed to manage the risk of PU formation are available, for example Mepilex Border (Mölnlycke Health Care) and foam dressings are often intended to manage the risk of PU formation.

Repositioning the patient is a critical part of removing pressure. Patients at-risk of PU formation should be repositioned every 2 to 4 hours so that they lie or sit with weight supported on a different part of the body. A number of products are available to ensure that the patient remains in the desired position. These include shaped blocks and foams that are placed against the patient to prevent rolling or movement back onto the vulnerable skin site. Examples include Devon Utility Pad (Aria Medical), Mölnlycke Z-Flo Fluidised Positioner Z3 and Z4 (Mölnlycke Health Care) and wedges and foams from a number of companies.

In practice, it is common not to have positioning aids and in this instance pillows can be used to help position the patient. Patients who are able to should be advised to reposition themselves no longer than every six hours (NICE 2017 preventing PU adults). In patients who cannot be repositioned because of their medical condition, where available a high specification pressure relieving mattress such as a low air loss or fluidised bed should be used. Where such a mattress is not available advice should be sought from the MDT, perhaps tilting rather than fully repositioning may be of benefit. However, the risk of PU development due to the inability to reposition should be discussed with the patient/relatives and MDT where available and clearly documented in the clinical notes.

**Friction and shear reduction**

Friction deforms skin and induces internal tissue stress when the patient moves, or is moved, by sliding on a surface such as a bed sheet. Friction is reduced by placing a low friction interface between the skin and the surface or by absorbing some of the deformation in the interface. Friction-reducing products should be used where the risk of friction—induced shear stress has been identified. Examples of friction-reducing interfaces include slide sheets distributed by several companies, and low friction bootees undergarments and pillow cases (APA Parafricta). Where low friction interfaces are not available great care should be taken when repositioning and moving of the patient.

**Skin care**

Barrier creams should be used to protect against moisture-associated skin damage (MASD). Massaging or rubbing the skin should not be used in prevention of PU. Hand movement used to apply protective creams should be enough only to ensure even spread. Spray dressing are also suggested as they are transparent and quick drying skin, examples include Opsite (Smith & Nephew), Cavilon (3M Ltd).

**Nutrition**

Where nutritional deficiency has been identified, and where available, a nutritionist should assess the patient’s dietary needs and advise on improvements to
minimise the effect of malnutrition.

Diabetic foot ulcer prevention

All patients with diabetes and loss of protective sensation, DPN, are at risk of developing a DFU. The purpose of a risk analysis is to identify those at highest risk, to stratify the risk, and to target preventative interventions optimally.

The start point for prevention of DFU is care standards as laid out in guidelines. The most widely-used worldwide guidelines on preventing DFU are those of the IWGDF (Bus et al 2016). Other guidelines include those prepared by NICE (NICE 2015 DF problems), the Task Force of the Foot Care Interest Group of the American Diabetes Association (Boulton et al 2008), the International Diabetes Foundation (IDF) (Ibrahim 2017), Saskatchewan Ministry of Health, (Saskatchewan MoH 2016) and the Wound Healing Society (Steed et al 2008).

The key components of prevention of DFU which should be followed according to the National Diabetes Programme Clinical Strategy and Programmes Directorate: (Ref)

- Nail care
- Emollient use
- Footwear
- Daily self-examination of the feet
- Not walking in bare feet
- Debridement
- Checking footwear and hosiery before wearing
- Breaking shoes in” never to be attempted
- No hot water bottles
- Checking bath and shower temperature
- Avoidance of home remedies e.g. corn plasters
- What to do and the appropriate person to contact

Table X. Recommended treatment and follow-up for patients in different risk categories for DFU formation (Boulton et al 2008)\textsuperscript{x}

<table>
<thead>
<tr>
<th>Risk category</th>
<th>Definition</th>
<th>Treatment/action recommendations</th>
<th>Suggested follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No LOPS*, no PAD**, no deformity</td>
<td>Patient education including advice on appropriate footwear Skin/callus/nail care</td>
<td>Annually (by generalist and/or specialist) or as needed</td>
</tr>
<tr>
<td>1</td>
<td>LOPS±deformity</td>
<td>Consider prescriptive or accommodative footwear Daily self-inspection. Routine skin/nail care Consider prophylactic surgery if deformity is not able to be safely accommodated in shoes. Continue patient education</td>
<td>Every 3–6 months (by generalist or specialist)</td>
</tr>
<tr>
<td>2</td>
<td>PAD±LOPS</td>
<td>Consider prescriptive or accommodative footwear Daily self-inspection. Routine skin/nail care Consider vascular consultation for combined follow-up Continue patient education</td>
<td>Every 2–3 months (by specialist)</td>
</tr>
<tr>
<td>3</td>
<td>History of ulcer or amputation</td>
<td>Same as category 1. Consider vascular consultation for combined follow-up if PAD present.</td>
<td>Every 1–2 months (by specialist)</td>
</tr>
</tbody>
</table>

\textsuperscript{x} LOPS, Loss of protective sensation; ** PAD, peripheral arterial disease
if foot problems develop.

The Task Force of the Foot Care Interest Group of the American Diabetes Association (Boulton et al 2008) and Saskatchewan MoH recommend the following approach to stratifying and managing the risk of DFU formation (Table xx).

The health-care services available to all persons living with diabetes should include the following (adapted from Saskatchewan MoH guidelines and others):

- Daily foot inspection/examination and risk assessment
- Nail care
- Callus care
- Skin care
- Foot hygiene
- Podiatric management
- Pressure reduction to foot (off-loading).

Appropriate selection of protective footwear includes:

- Commercially available shoes with designed for the diabetic foot may be adequate for low-risk patients
- Added depth shoes should be recommended for high-risk patients who have DPN, vascular insufficiency and/or mild to moderate foot deformity (a custom moulded inlay may be needed)
- Custom molded shoes with custom inlays should be recommended for high-risk patients with advanced deformity
- Patients should be advised not to walk at any time without wearing protective footwear.

Further information on foot ware for patients with diabetes can be found in updated recommendations from Diabetic Foot Australia. (Jaap J. van Netten)

In addition to the measures that the patient should adopt (Table XX), the temperature of the foot should be assessed and where higher than normal the patient should refer to a health professional. High temperature may indicate tissue breakdown and/or infection. Foot inspection may be assisted by the use of a mirror. However, patients with diabetes may have impaired vision because of retinopathy and should be assisted by a helper who has been educated in how to inspect the foot.

Management

Navigating the patient through the pathway

The first step is to identify a clinician who is the ‘wound care navigator’ (WCN). The job title of the WCN is less important than the ability to fulfil the requirements of the role. The role of the WCN is to conduct an appropriate assessment and refer quickly where needed. The job function of the WCN will vary from country to country but the person should be trained and able to do the following:

- Assess the patient to identify those at risk of PU or DFU formation
- Take a patient history
- Identify the basic characteristics of the ulcer (location, size, depth, presence of necrosis, pain, signs of infection)
- Conduct simple tests to identify if an ulcer is most likely to be a PU or a DFU, particularly when the ulcer is on the heel (pulse palpitation is crucial)
- Identify the additional tests and assessments required to fill in the gaps in knowledge and competencies
- Identify the appropriate care pathway and clinician to whom the patient should be referred
- Be aware of the urgency of the referral (i.e. a patient with ascending cellulitis or gas gangrene, necrotising fasciitis needs to be referred immediately).

Additional skills may include: administer a monofilament test and/or vibration perception test; administer ABPI test; perform a doppler ultrasound; and wound management.
The level of training and competence of the WCN may be at a basic level. Where competence does not include conducting pulse palpation and/or a basic toe touch test, the WCN should know how, and to whom, to refer the patient. At the basic level, no specialist equipment is required to assess the patient. In the case of a possible heel PU or DFU, sensation and neuropathy is assessed by the IpTT and vascular status is assessed by pulse palpation.

**Wound management**

Where possible clinically a PU or DFU should be managed to ensure timely ulcer closure. A DFU that does not heal is a risk for amputation; rapid ulcer closure is therefore highly desirable. Standards of care specific to the management of PU and DFU have been published by a number of organisations (National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance 2014; NICE 2014. Pressure ulcer management. The prevention and management of pressure ulcers CG179; Gould et al 2016; Hingorani et al 2016; IWGDF. Prevention and management of foot problems in diabetes 2015; IWGDF Guidance on footwear and offloading interventions 2015; Saskatchewan Ministry of Health 2016; International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. Wounds International; Bolton et al 2014; Nather et al 2015; NHS SSKIN Bundle). However, where available local guidelines should be followed.

There are also a number of generic guidelines on principles of best practice in wound management, for example Wound Bed Preparation, TIME, MOIST, have also been published (Sibbald et al 2011; Harries et al 2016 Dissamond JWC 2017). These provide information on how the major areas that must be considered when preparing the wound bed to aid healing.

The principles of ‘TIME’ are a used to guide health professionals on what to assess and treat in the wound bed:

- Moisture balance
- Epidermal margin; non-advancing or undermined.

Over the years these principals have been modified to include other markers such as TIME-H which include and healing score (REF). Another variation on the TIME principal recently developed by the German wound association, Initiative for Chronic Wounds (ICW) e.V is MOIST. (adapted from Dissemond et al)

- Moisture balance: exudate management, ensure that wounds are neither too moist nor too dry
- Oxygen balance: in the pathophysiology of chronic wounds hypoxia plays a decisive, central role in nearly all types of wounds
- Infection control: all antimicrobial strategies in wound therapy regimes
- Support: if, despite an apparently adequate therapy, wounds do not heal, specific wound care agents can be used temporarily
- Tissue management: all measures of conditioning the wound bed, for example, neutral wound dressings, biosurgery or physical aids such as negative pressure, electricity, plasma, or ultrasound.

MOIST covers the general principals of TIME and includes a section on oxygen balance, which if comprised will hinder wound closure and may be of particular importance in ischaemic DFUs.

**General principals of wound management**

The general principles of effective wound management, embodied in all guidelines in slightly different ways, should be implemented for PU and DFU. The principles common to all guidelines include the following steps:

1. Assessment and diagnosis
2. Develop care plan
3. Management of the underlying condition and causes (including off-loading for DFUs and pressure relief for PUs)
4. Management of exudate
5. Manage bioburden, biofilm and infection
6. Debridement
7. Nutrition and hydration
8. Monitor progress and adjust care plan

In the next section the processes (excluding assessment and diagnostics) and procedures recommended for the management of the wound, and the underlying condition and causes, to maximise the probability of healing.

These steps may be achieved with products that range from low cost and basic to the high cost and advanced. Care should be delivered using products that have evidence-based data on their effectiveness in the local population. Effectiveness may be measured by clinical effectiveness of efficacy and health economic analysis.

Health economics in particular are specific to the patient population and health-care delivery system in which the analysis was conducted. Assessment and diagnosis has been covered in detail in section 3.

**Care plans**

A care plan describes how the patient will be managed based on the outcomes of assessment and diagnosis. The plan covers the care that needs to be delivered, using which procedures and processes, competencies required to deliver the care, and where treatment will take place. Referral is part of the care plan (section 3) because it requires an assessment to have identified what needs to be delivered and the competencies, and therefore, the health professionals who should be involved.

**Managing the underlying condition**

---

**Fig XX Management and treatment flowchart**

**Diabetic foot ulcer**
- **Management**
  - Relieve pressure:
    - Offloading:
      - Non-removable total contact casting (TCC)
      - If ischaemic consider a removable system
      - Other options include knee-high walkers, forefoot shoes, and custom-made temporary shoes

**Pressure ulcer**
- **Management**
  - Relieve pressure:
    - Repositioning
    - Dressings
    - Mattress (High quality foam hybrid systems, alternating systems)
    - Anatomy-specific products (boots, etc)
    - Low friction materials (slide sheets)

**At 4 weeks reassess ulcer**
- **Has the wound size decreased by ≥50%?**
  - Yes
    - Continue with standard care
  - No
    - Change care plan. Consider other/advanced technologies

---
and causes

Delayed wound healing is consequence of the wound being stuck in the inflammatory stage of the healing cycle. Trapped in this inflammatory phase there is an excess of inflammatory molecules, including inflammatory cytokines, free radicals, and proteases such as matrix metalloproteinases (MMPs) and tissue inhibitors matrix metalloproteinases (TIMPs) released, which become harmful to the wound bed and periwound area, disrupting wound healing (3,4).

The molecular basis of incomplete wound healing and the change from an acute to a chronic wound is a major focus of attention in wound healing research in patients with diabetes. (19-22). DFUs have a prolonged inflammatory phase with fibroblast dysfunction, impaired neovascularisation, and increased concentrations of MMPs. This excess of MMPs clearly alter wound healing process through degradation of the extracellular matrix (ECM), affecting both the control of the activities of various effector proteins such as growth factors and the deposition of new ECM (3, 4). DFUs often fail to heal because of persistently high levels of pro-inflammatory cytokines in the wound, which induce high levels of MMP. These subsequently destroy growth factors, receptors and matrix proteins essential for wound healing. MMPs are also responsible for the controlled fragmentation of the basal membrane, induction of inflammation and angiogenesis, as well as for epithelialisation. Most likely, the balance between MMP and TIMP levels plays a crucial role in successful wound healing. Modulation of MMPs in the wound area as well as other regulating factors of wound healing (e.g. PDGF, FGF, EGF, cytokines, etc.) become more relevant and indicate that this could be a further benefit in the treatment of chronic wounds. However, many of the molecular mechanisms responsible for wound healing remain to be elucidated, and very little is known about differences in different wound types.

Patients with diabetic foot syndrome often display a functional vascular impairment caused by a thickening of the basal membrane and endothelial capillary swelling. As a consequence of the developed neuropathy, the endothelium-dependent regulation of the vascular lumen is affected by nitric oxide (NO) and the neuronal regulation of the precapillary arterioles is deregulated. Due to such dysfunctions, an adequate reaction in the foot to an injury like an increased blood flow in response to the high demand of oxygen and nutrient cannot be achieved. Although the feet of patients with diabetes seem phenotypically healthy, such underlying structural and molecular changes may prevent a sustained oxygen supply when needed after an injury. Dissemond et al 2015 85 An important consideration in physiologic wound healing is oxygen supply and oxygen tension in the wound bed. The oxygen balance in wounded tissue is an important challenge, as it affects all other aspects required for appropriate wound healing. 2 3-6 (REF)

Pressure ulcers: Pressure, friction/shear and moisture should be managed, with methods that achieve pressure reduction and redistribution are generally the same as those used for PU prevention and include pressure relieving and redistribution surfaces, anatomy-specific products such as heel protection boots, dressings, and repositioning the patient (see section X).

Moisture management should include barrier creams, and methods to contain and control incontinence. An active PU is itself is a source of moisture. Please refer to the section on ‘managing exudate’ for more detail.

Local treatment guidelines where available should be used however, examples include using the SSKIN bundle with treatment tailored to the condition of the wound.

Diabetic foot ulcers: Blood flow, neuropathy and foot deformity leading to pressure, and infection should be managed. These are components of VIPS.

As discussed earlier every patient with a DFU should have a vascular assessment. If a patient has tissue loss and an ABPI of ≤0.90 that will require vascular
review, similarly, if the patient has tissue loss and a toe pressure of <50mmHg that necessitates vascular review as a toe pressure of <50mmHg has been associated with impaired healing. Other suggested examinations before referral are; pulse palpation, doppler isonation with mono/bi/tri sound. With Doppler isonation a monophasic pulse would be abnormal and necessitate further assessment/referral, as the presence of a monophasic Doppler is considered indicative of PAD.

Neuropathy leads to inability to sense pain in the foot. Patients with neuropathy may wear shoes that are too tight because they cannot feel when they do not fit correctly. Furthermore, loss of sensation means that a wound or object in the shoe that could cause injury to go unnoticed, this coupled with repetitive trauma from walking and ulcer will deteriorate. Furthermore, deformity causes high pressure points which are vulnerable to damage. All patients with neuropathy and a DFU should wear correctly fitted offloading footwear. Amputation leads to abnormal high pressures underneath the foot and requires offloading customised to the foot shape.

The optimal offloading method associated with the highest rate of full DFU closure in the shortest time is non-removable TCC (BSN Medical) (Armstrong et al 2001; Lavery et al 2014; Lewis et al 2013, Snyder et al 2014). The foot is closely fitted with a cast that distributes pressure over the entire plantar surface of the foot. This is achieved by building up layers of filling and padding that accommodate the foot deformity and encasing it in a plaster cast to maintain pressure redistribution. TCC application is highly skilled and should be done by health professionals fully trained in the technique, to minimise the likelihood of rubbing causing additional damage and to optimise pressure redistribution. In general, the initial change will take place 2–3 days after the first cast is applied (to ensure that everything is OK). Afterwards, the cast will generally be changed about once a week or as determined by the health professional, to accommodate any reduction in limb size as oedema reduces and to inspect the skin and foot for damage. A TCC alternative that is easier to apply, but still requires training, is the TCC-EZ (Derma Sciences). This product may be considered instead of traditional a TCC.

Where the competency for traditional non-removable TCC or TCC-EZ is not available other removable footwear options for offloading should be used when appropriate to the health-care system and the patient’s preferences. These include knee-high walkers, forefoot shoes, and custom-made temporary shoes. DFU heal less well with removable offloading compared with non-removable TCC because devices are often removed and not used when the patient walks. Non-use reduces the offloading delivered to the foot, impeding effectiveness. It is important therefore to ensure that the patient will adhere to wearing the offloading device at all times when ambulatory, even in ‘safe’ environments such as the home. The offloading must be fitted with an interface between the foot and the internal surfaces of the device to ensure optimal pressure redistribution. Where offloading devices are not available, felted foam should be used. An alternative is complete pressure removal with crutches, walkers, wheelchairs or foot elevation. Where possible, all neuropathic and ischaemic DFU should be managed with offloading.

Where offloading is not successful further options, as required after assessment by the MDT, are required such as surgical intervention to correct deformities.

**Management of exudate**

Exudate from a chronic wounds not only increases skin moisture when in contact with the surrounding skin, but also contains destructive biological molecules including protein-degrading enzymes that may harm the wound bed and periwound skin. It is important to minimise the amount of exudate that comes into contact with skin and the duration of contact for both PU and DFU. Exudate is generally managed by dressings or negative pressure wound therapy (NPWT).
Dressings provide a cover to the wound to help manage ulcer contamination from exogenous sources and the dispersal of organisms from the wound to the environment. There is widespread agreement that the ulcer should be maintained in a moist warm environment to encourage healing. Some authorities advise that gauze should not be used, and that the least expensive dressing that fulfils the clinical requirements should be used. Local guidelines should be followed. Dressing selection depends on several factors including:

Table X. Consideration for standard pressure ulcer care.* Note these will vary for region to region as with protocols for standard care. Always refer to local guidelines

<table>
<thead>
<tr>
<th>Consideration for standard PU care</th>
<th>Examples</th>
</tr>
</thead>
</table>
| Manage pressure/shear and friction | Repositioning (foam)  
Dressings. Silicone multi-layered foam dressings (Mepilex Border, Mölnlycke;  
Allevyn, Smith & Nephew)  
Mattress (High quality foam e.g. Trezzo, HS, hybrid systems, alternating systems)  
Anatomy-specific products (boots, etc)  
Low friction materials (Paraflecta bootees, slide sheets)  
Skin protectants (Cavilon, 3M Ltd; Opsite, Smith & Nephew; Remedy Olivamine Dimethicone Skin Protectant, Medline Industries; Secura, Smith & Nephew) |
| Debridement options | Dressings (Debrisorf, L&R; Hydroclean plus, Hartmann)  
Hydrosurgery pressurised water (Versajet, Smith & Nephew)  
Larval/maggot debridement therapy (Biobag, BioMonde; Medical Maggots, Monarch Labs)  
Pulse lavage (Microaire Stryker) Microaire, pulsecare medical)  
Ultrasonic debridement therapy (Sonoca, Söiring, SonicOne, Misonix)  
Surgical/sharp |
| Early diagnosis and treatment of Infection | Assess clinical signs of infection:  
PTB, Simple X-Ray, C-reactive protien (CRP), Erythrocyte Sedimentation Rate (ESR), Leuocytosis, Treatment accoding infection severity |
| Prevention and treatment of infection (biofilm) and inflammation | Cadexomer iodon, antimicoribial (Iodosorb, Smith & Nephew),  
Dialkylcarbomoyl chloride (DACC)-coated dressings, bacterial binding and inactivation (Sorbact: BSN)  
Honey, antimicrobial (Actvion, Advancis; Surgihoney RO, Matoke Holdings Limited)  
Polyhexamethylene biguanide (PHMB), antimicrobial (Kerlix AMD Antimicrobial, H&R Healthcare)  
Prontosan, antiseptic (B Brawn)  
Octenidine, antiseptic (Octenisept schülke)  
Silver, antimicrobial (Acticoat, Smith & Nephew; Aquacel Ag, Convatec; Sorbasan silver, Aspen Medical)  
Sucrose octasulfate, MMP modulator, aids neovascularrision (UrgoStart Contact, Urgo Medical Laboratories)  
Superoxidized water, antiseptic (Microcyn, Dermacyn) |

*note: the table contains examples of products and technologies and is not an exhaustive list
The site and size of the ulcer
The amount and type of exudate
The stage of healing of the ulcer and predominant tissue type
The integrity and condition of the surrounding skin
The quality of the patient’s skin
The patient’s tolerance of adhesives
Pain

Comfort and QoL
The anticipated frequency of dressing change
The need for topical antimicrobial management of the ulcer
Compatibility with other elements of the overall care plan
Cost
Availability and formularies

Table X. Consideration for standard DFU care*. Note these will vary for region to region as with protocols for standard care. Where available always refer to local guidelines or IWGDF guidelines

<table>
<thead>
<tr>
<th>Consideration for standard DFU care</th>
<th>Examples</th>
</tr>
</thead>
</table>
| Metabolic control and management of the comorbidities | Control glucose levels  
HbAc1  
Renal function (Creatinine, Albumin)  
Random urine microalbumin, proteinuria |
| Assess vascular status | Pulses palpation  
ABPI and wave form  
Ankle systolic pressure  
Toe systolic pressure  
TCPO2, Tissue perfusion |
| Offloading | Non-removable total contact casting (TCC) (XXX)  
If ischaemic consider a removable system TCC-EZ (Derma Sciences).  
Others options include knee-high walkers, forefoot shoes, and custom-made temporary shoes. |
| Debridement and callus removal | Preferably surgical, except when ischaemia is present, in this case consider other techniques: UAWD (XXX), autolytic, enzymatic  
Podiatric drill for callous removal |
| Early diagnosis Infection | Assess clinical signs of infection:  
PTB, Simple X-Ray, C-reactive protein (CRP), Erythrocyte Sedimentation Rate (ESR), Leucocytosis,  
ATB treatment according to infection severity (IDSA/IWGDF guideline, guidance) (XXX) |
| Prevention and treatment of infection (biofilm) and inflammation | Cadexomer iodine, antimicrobial (Iodosorb, Smith & Nephew),  
Dialkylcarbomoyl chloride (DACC)-coated dressings, bacterial binding and inactivation (Sorbact; BSN)  
Honey, antimicrobial (Acticon, Advancis; Surgihoney RO, Matoke Holdings Limited)  
Polyhexamethylene biguanide (PHMB), antimicrobial (Kerlix AMD Antimicrobial, H&R Healthcare)  
Silver, antimicrobial (Acticoat, Smith & Nephew; Aquacel Ag, Convatec; Sorbasan silver, Aspen Medical)  
Sucrose octasulfate, MMP modulator, aids neovascularisation (UrgoStart Contact, Urgo Medical Laboratories) |

*note: the table contains examples of products and technologies and is not an exhaustive list
Management of bioburden, biofilm infection and inflammation

Bioburden, and biofilm in particular, is believed to impede healing (Phillips et al 2010). At least 60%, and possibly all, of chronic wounds have mature, established biofilm on the surface and in deeper tissues (Schultz et al 2017, Malone et al 2017) and it is challenging to diagnose clinically (Schultz et al 2017). There are no biofilm-specific markers and it cannot be seen by the naked eye. The diagnosis that biofilm is contributing to impeded healing is therefore made by eliminating other factors that may impede healing. When assessment suggests that biofilm contributes to impaired healing, early intervention is recommended. New regimens are being suggested such as biofilm-based wound care (BBWC) (Schultz et al 2017), which aim to disrupt and suppress biofilm allowing local antimicrobial agents to kill the bacteria.

However, a gradually de-escalating regimen, informed by assessment of inflammation and healing, is recommended. Starting on days 1 to 4, aggressive debridement, topical antiseptics and systemic antibiotics, management of underlying host factors, and profiling microorganisms using genetic methods are recommended (Schultz et al 2017). Treatment is de-escalated with regular debridement and wound cleansing as healing improves. Genetic profiling of microorganisms is highly specialised and available in few institutions. Where required, standard microbiological evaluations may be conducted using swab, or preferably biopsy, specimens.

Microbiological analysis is used to direct antibiotic therapy, not to diagnose infection. Many guidelines contraindicate systemic antibiotics where clinical infection is absent. Local guidelines should be followed. Antimicrobial agents do not improve healing in wounds where bioburden is not the cause of impaired healing. Their effect is to help manage bioburden which in turn impairs healing. Antimicrobial dressings are not generally recommended for preventing secondary infection but may be recommended for mild clinical infection. Topical antiseptics/antimicrobials should be used where a microbiological cause of impaired healing has been identified. They should be used for up to two weeks, and the wound regularly re-assessed. If healing has improved, topical antiseptics/antimicrobials should be stopped and non-antimicrobial dressings used. If healing has not improved, the wound should be assessed to decide whether to continue the current antiseptic or to switch to a different antiseptic. Assessment should include factors other than ulcer bioburden that may be impairing healing.

Clinically-diagnosed infection should be managed using systemic antibiotics. Topical antibiotics are not recommended, and are associated with increased risk of development of antibiotic-resistant organisms. Antibiotics should be selected based on ulcer specimens and antibiograms. In severe infection, particularly in the DFU, immediate empiric broad spectrum parenteral antibiotics should be administered as per local guidelines. Once the sensitivity data are available from the microbiology service, antibiotics should be customised to the patient. Duration of antibiotic therapy should be according to clinical assessment outcomes. Antibiotic stewardship guidelines should be followed. Management of infection includes surgical drainage of abscesses and excision of infected bone.

Microbiological specimen collection may be achieved using one of a number of methods according to local practice and guidelines. General principles include:

- Specimen should be collected before starting antibiotics
- The ulcer should be debrided and cleaned before specimen collection
- Specimens should be transferred quickly to transport medium to preserve the specimen
- The request should include tests for aerobic and anaerobic organisms and antibiotic sensitivity
Sampling methods include pus collected from the deepest part of the wound, swabs (a number of swabbing methods are available), aspiration, tissue biopsy, and for osteomyelitis, bone biopsy. Osteomyelitis should be suspected if a probe or finger touches bone. (Lavery) Antibiotic therapy should be continued for up to six weeks for osteomyelitis. Additional diagnostic procedures for osteomyelitis such as X-Ray, MRI, CT scanning and other advanced methods may be used where available. Where systemic infection is suspected, blood cultures should be done. For further reading see Harries et al 2016 which explains the different forms, infection prevention and management.

Impaired neovascularisation and excess of MMPs are two majors’ factors impeding the healing of chronic wounds especially the ones encountered with vascular insufficiency (1, 2). The potassium salt of sucrose octasulfate (NOSF, Nano Oligosaccharide Factor) acts at the tissue level and has been shown to inhibit excess MMPs (5, 6), in result of the stalled inflammatory stage of wound healing. In addition, the NOSF has a unique structure that interacts with growth factors and thus restores their biological functions contributing to tissue formation and leading to the reactivation of vascular cells migration and proliferation (7-9). In a recent RCT the sucrose octasulfate dressing significantly improved wound closure of neuroischaemic DFUs.

Debridement
Debridement is an important component of a good standard of wound management. Debridement removes callus, unwanted and dead tissue, and slough from the wound. It enables accurate assessment, helps drainage, improves healing, removes biofilm, and removes a reservoir of potential infection. Debridement may be accomplished by a number of methods which should be selected according to clinical assessment, the needs of the wound, local practice, and availability of equipment and competencies. Debridement methods include:

- Autolytic: hydration of tissue to allow natural host proteolytic enzymes to remove devitalised tissue. Hydration is obtained in dry tissue using hydrogel or honey
- Enzymatic: exogenous proteolytic enzymes used to dissolve devitalised tissue. The efficacy of enzyme debridement is thought unproven by some authorities
- Larval: ‘biosurgery’. Use of greenbottle fly larvae to remove devitalised tissue selectively. Cannot remove callus. Larvae must be prepared by specialist suppliers
- Surgical sharp: invasive debridement with surgical instruments under anaesthesia for sensate patients, anaesthesia may not be required in neuropathic DFU. Surgical debridement should be conducted only by competent practitioners. A curette may be used to scrape loose material gently off the wound. Pain management may be required
- Hydrosurgery: mechanical debridement with pressurised water jet to dislodge and remove devitalised tissue
- Ultrasonic (Haycocks and Chadwick 2008; Wounds UK effective debridement): ultrasound and fluid to remove devitalised tissue mechanically. Relatively recent introduction means it may not be widely available.

Health professionals must be able to distinguish tissues and structures to avoid damaging the local anatomy while debriding and have a high level of clinical decision-making to control the extent of debridement. An old mechanical technique known as ‘wet-to-dry’, in which a wet gauze is allowed to dry on the wound and then pulled off, is no longer recommended because it causes pain for the patient and removes tissue indiscriminately causing trauma.

For PU debride only when clinically indicated by the presence of devitalised tissue or slough and when there is adequate tissue perfusion to the wound. Any of the debridement methods may be used taking into account the size and depth of the PU, clinical requirement for speed of debridement, patient tolerance especially with surgical debridement, comorbidities and the care plan which may include...
grafting for which a clean recipient wound bed is essential. Surgical debridement is appropriate for PU with extensive necrosis, advancing cellulitis, crepitus, fluctuance, and/or sepsis secondary to ulcer infection. Larval debridement may be considered where sharp debridement is contraindicated.

For DFU debridement has been shown to improve DFU healing (Steed et al 1996). Where available the widely-accepted standard is sharp debridement using scissors or scalpel and forceps. Vascular status should be confirmed before debridement and compromised tissue should not be surgically debrided. Non-surgical debridement should be used where the required competencies are not available or in patients who cannot tolerate surgery. Larval debridement may be considered if it is available.

**Nutrition and hydration, glycaemic control**

Good nutritional status is required for optimal healing. Patients should be assessed by a nutritionist or other health professional competent to conduct a nutritional assessment and diet and fluid intake adjusted according to clinical need.

The following tools could be employed to assess status:

- Malnutrition Screening Tool (MST) (REF)
- Mini Nutritional Assessment (MNA) – short form and long form (REF)
- Malnutrition Universal Screening Tool (MUST) (REF)
- Subjective Global Assessment (SGA) (REF)

Note: in developing countries the dietician and not the nutritionist perform the dietary assessments and they using their Dietitic Care Notes DCN.

**Monitor progress and adjust care plan**

The ulcer should be inspected and assessed at least weekly to monitor progress. Where clinical improvement is not seen, regular assessment will indicate an alternative care plan which should be documented and implemented. An accepted time point is 4 weeks following the start of DFU treatment when the ulcer should be assessed using the methods previously described. Healing progress measured as area reduction and wound bed improvement at this time point is generally regarded as an indicator of the likelihood of complete ulcer healing (Cardinal et al 2008; Coerper et al 2009; Margolis et al 2003; Sheehan et al 2003). In cases where the ulcer size has reduced by <50% at 4 weeks, an alternative care plan should be considered. The new care plan may need referral for tests and evaluations or other more advanced interventions where local guidelines recommend them. These may include advanced therapies (see section 6) or surgical procedures for debridement, grafting or vascular reconstruction. In the US, the Centre for Medicare and Medicaid Services (CMS) uses the 4-week statistic as a trigger for reimbursement of advanced therapies. Other jurisdictions advise not using some advanced therapies because the health economic advantage has not been adequately proven.

Where the expected clinical progress is met, treatment should continue according to the care plan.

**Prevent recurrence**

Prevention has already been covered in detail in this section, however it is worth mentioning certain treatments should be performed until complete closure of wounds to avoid recurrence of infection/slough/exudate/pain or to stall wound healing.(Ref Hunt 2018) Note: main causes for recurrences in DFUs are: location of the ulcer (plantars surface and specially beneath 1st Metatarsal Head), use of non-appropriate shoes, presence of foot deformities and previous amputation.
Treatment of PU and DFU is not effective for every patient; some wounds do not heal in a time frame consistent with expectations and clinical experience. When this happens alternative approaches are required, including new or advanced therapies. This modification of the care plan which must be founded on objective information. A stepwise approach based on detailed patient assessment should be adopted.

This section looks at some of the options and alternatives available, recognising that these options are not available in all countries and that where they are available, national guidelines and payment systems may not cover their use. It should also be noted therapies are suggested here and in the standard care options, this reflects the current differences in standard care preferences worldwide. Furthermore, for a full review of new advanced therapies see the EWMA document on ‘Advanced therapies on wound management’. Piaggesi et al (EWMA document Published June 2018)

What to do if not healing with standard care

If standard care has failed to lead to a reduction in the wound size ≥50% over four weeks, (Cardinal et al 2008; Coerper et al 2009; Margolis et al 2003; Sheehan et al 2003) the first step is a thorough and detailed reassessment of the ulcer and the patient. The accuracy of the original diagnosis should be validated and the treatment choices reviewed. Has the underlying condition changed? New tests may be required. For example where a basic test such as pulse palpation was carried out, would better information be provided by a more advanced test such as a full vascular work up, if available? Perhaps a basic IpTT or vibration perception threshold test gave inaccurate information. Would a more detailed analysis of nerve conduction provide better diagnostic fidelity? Where a diagnosis of uninfected was made, would a white blood cell count or C-reactive protein (CRP) test give more helpful information? Is there something about the wound such as carcinoma that was previously not detected?

Once the assessment has provided up-to-date information and it is confirmed that the previous standard of care was correct, it may be appropriate to consider other therapies and more aggressive treatment regimens. A benchmark for making a decision on switching to advanced therapies is the healing response after four weeks’ care with best practice (Cardinal et al 2008; Coerper et al 2009; Margolis et al 2003; Sheehan et al 2003). If healing, measured by wound area reduction, has not reached ≥50% compared with the start of treatment then a switch to other therapies may be indicated.

The advancement may be escalation of the intensity of treatment or a change to a different way of managing the condition of the ulcer. Some examples are detailed below, this is not an extensive list but aims to provide examples for consideration.

Diagnostic methods

There are more advanced methods to assess PAD, such as magnetic resource angiograms or computer tomography angiograms, which may be performed by a vascular specialist if required.

Early detection of sub-epidermal moisture (SEM) changes can be measured using the electrical

Key points

- If the wound has not healed by ≥50% over four weeks reassessment is required
- Debridement may need to be more aggressive if healing is stalled
- Where offloading is not successful non-removable or complete offloading may be appropriate
- Diagnostic tools can aid the choice of new treatment
- Use therapies that are evidence based
properties of skin (bioimpedance) (Bates-Jensen et al 2017; Moore et al 2017). A recent literature review concluded that the SEM Scanner (Bruin Biometrics) is an objective and reliable method of local bioimpedance, and therefore, assessment of tissue damage before there are visible signs of present. (Moore 2017).

Advances in detection of bacteria on the wound surface have been made and a violet light-based product (Moleculight i:X; distributed by Smith & Nephew) has been made available. Moleculight uses light at wavelength 405nm that reveals fluorescent metabolites of bacteria, principally porphyrin that fluoresces red (Rennie et al 2017) and pyocyanin produced by *Pseudomonas aeruginosa* that fluoresces green. Moleculight helps the practitioner visualise where bacteria are located in the wound to target and monitor debridement for effectively. (Blackshaw & Jeffery 2018).

Point of care swab tests may also aid the assessment of whether wounds are non-healing due to elevated host protease activity or bacterial pathogenesis. WOUNDCHEK Bacterial Status detects bacterial protease activity, a common virulence factor which is indicative of pathogenic behaviour of bacteria in the wound before clinically observable infection, at a point in the infection continuum where antimicrobial treatment is typically required. (REF) WOUNDCHEK Protease Status detects elevated host protease activity (MMPs and neutrophil elastase) a marker of chronic wound inflammation. A discussed earlier (XXX) elevated inflammatory proteases can disrupt wound healing unless appropriate intervention e.g. a protease modulating dressing. (REF)

---

**Table X. Potential therapies to consider if not part of local standard care*. Note these will vary for region to region as with protocols for standard care. Always refer to local guidelines**

<table>
<thead>
<tr>
<th>Treatment of Infection and biofilm</th>
<th>Antiseptics (XXX)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antimicrobial (XX)</td>
</tr>
<tr>
<td></td>
<td>Antibiofilm (Cadexomer iodine)</td>
</tr>
<tr>
<td></td>
<td>Technologies (SteriPlasma, AdTech)</td>
</tr>
<tr>
<td>Exudate management</td>
<td><strong>Dressings</strong> (Cutimed Sorbion: BSN)</td>
</tr>
<tr>
<td></td>
<td>NPWT (PICO, Smith &amp; Nephew: Renasys touch, Smith &amp; Nephew: Snap, KCI)</td>
</tr>
<tr>
<td>Topical agents/ healing enhances</td>
<td>Oxygen delivery (Granulox, SastoMed; Natrox, Inotec; epiflo- Ogenix)</td>
</tr>
<tr>
<td></td>
<td>MMP-modulators (Promogran, KCI)</td>
</tr>
<tr>
<td></td>
<td>MMP modulatorUrgoStart, Urgo)</td>
</tr>
<tr>
<td></td>
<td>Biologics/skin substitutes (Apligraf, Organogenesis; Dermagaft, Organogenesis; EpiFix, MiMedix, the Omnigraft product (integral))</td>
</tr>
<tr>
<td>Diagnostic methods</td>
<td>Bacteria identification (Moleculight i:X)</td>
</tr>
<tr>
<td></td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>XXX</td>
</tr>
</tbody>
</table>

*note: the table contains examples of products and technologies and is not an exhaustive list
Advanced technologies and alternative therapies

Preliminary data has also suggested that an hyperspectral imaging (TI-CAM, Diaspective Vision GmbH) system maybe useful as a diagnostic tool to help aid helf professionals decide on treatmens options by provide rapid tissue perfusion measurements including superficial oxygenation (StO2 [%]), Tissue Hemoglobin Index, NIR Perfusion Index and Tissue Water Index in the wound. (Wilde JWC). By combining the various pieces of information, it maybe possible to get a holistic picture of the condition of wounds.

Debridement
Debridement may need to be more aggressive to remove devitalised tissue to a healthy wound bed. Where access to the operating theatre is possible this is often achieved by surgical debridement. Other less aggressive debridement methods may be effective at removing biofilm without causing discomfort to the sensate patient. This in itself may enable better debridement because the patient is able to tolerate the procedure better. An example is monofilament debridement pads (Schultz et al 2018). An alternative to sharp surgical debridement is hydrosurgery using a pressurised water jet to remove devitalised tissue (Vanwijck et al 2010). This method may cause less pain and discomfort to the patient and be more suitable for patients who cannot tolerate surgery. Larval debridement or ultrasonic debridement. Ultrasonic debridement should be considered especially in DFU with grade of ischaemia when surgical debridement is contraindicated.

Managing infection
The cornerstones of managing infection remain wound cleansing and debridement and antimicrobial agents. More aggressive debridement may be required to ensure that all reservoirs of infection and sites of potential re-infection have been removed. Once achieved a change to a different topical antiseptic may be appropriate in combination with systemic antibiotic therapy. In osteomyelitis very aggressive removal of bone and use of high concentration antibiotics in slow release formulations retained in contact with remaining bone may be appropriate. [Panel can you check this please] Prophylactic antibiotics are not appropriate for all patients but where the risk justifies it then prophylaxis may be required.

Offloading
In most cases offloading can be achieved with low technology and relatively low cost products. Where offloading is not successful, perhaps because the patient removes it or there has been previous amputation that has created difficulty in effectively offloading the foot then use of non-removable offloading or complete offloading using crutches or a wheelchair may be appropriate.

Bioburden and biofilm
Options for management of bioburden and biofilm include products containing cadexomer iodine (Iodosorb) a well-established topical antimicrobial that also assists in desloughing. As the iodine is consumed cadexomer iodine changes colour providing an indication of when it need to be changed.

An alternative the microbicidal activity of iodine is physical removal of organisms. An example is dialkylcarbamoyl chloride (DACC)-binding dressings (Cutimed Sorbact, BSN Medical) that facilitates the passive hydrophobic binding of organisms which become trapped in the dressing and removed at dressing change. (ref) Advantages of this sort of therapy include lack of bacterial resistance, antibiotic-resistant bacteria are attracted to the product, non-allergenicity, no cytotoxicity, and because organisms are not killed endotoxins are not released. XXX

Exudate management
Where exudation from the wound is high options include highly absorbent dressings and negative pressure wound therapy (NPWT). Highly absorbent
Advanced technologies and alternative therapies

Dressings are able to absorb and retain large amounts of exudate removing it from the wound and keeping it isolated from the skin. An example is Cutimed Sorbion (BSN Medical). Where the amount of exudate is too great for dressings, NPWT is a long-established alternative. Examples include RENASYS TOUCH (Smith & Nephew) for highly exuding ulcers and PICO (Smith & Nephew), a portable low-profile product that does not use a renewable reservoir but is designed to absorb exudate into the dressing and take advantage of a high moisture vapour transmission rate to help manage fluid. VAC

**Healing enhances**

Outside of the normal category of therapies that are known to aid wound healing, there are adjunct therapies where which do not fit in to the areas describes here.

In recent years, topically applicable adjunctive therapeutic options have been developed in this area of wound care. All approaches aim to deliver oxygen locally to increase the oxygen concentration in a specific area where it is most needed at a particular time. It is known that wound healing has a high oxygen demand. In many cases, DFUs and PUs develop a hypoxic wound situation which requires additional oxygen supply. One such product is Granulox (Sastomed), a spray which enhances the oxygen diffusion by using purified haemoglobin. Based on the available clinical evidence (Gottrup 2017, Grade 1B) it has successfully be implemented in treatment regimens of PU and DFU.

Other available local oxygen therapies deliver an oxygen-rich atmosphere to the wound area, either by topical continuous delivery of non-pressurised (normobaric) oxygen (CDO) through small cannulas or thin tubes (Natrox/Epiflo) to wound dressings or by small chamber-based constant pressure devices (TWO2/TO2). (Gottrup et al 2017, Dissemond et al 2015)

Although already discussed, another healing enhancer which should be considered if not already used is sucrose octasulfate (Urgo Start) which has been shown to be effective in a number of chronic wound most recently in a RCT on neuroischemic DFUs. (LANCET Edmonds)

Growth factors (GF) and tissue equivalent (TE) products are available although not in all markets. GFs include becaplermin (e.g. Regranex; Smith & Nephew) and TE products for which a range of cellular or acellular extracellular matrix-based sheets are commercialised (e.g. amniotic membrane allografts, foreskin derived bioengineered grafts, split thickness skin grafts). Many authorities do not recommend GFs and TE). These products are reimbursed by CMS in the US once the 4-week clinical response threshold has been reached. z

I would add in this category of "Healing enhances", the Omnigraft product (Integra), which has a recent positive RCT in the management of DFU (Driver. WRR 2015)

**Biologics/skin substitutes**

Advanced treatment modalities that are cost effective and time sensitive are often indicated for chronic non-healing wounds to facilitate wound closure. Recent advances in wound care technologies, especially the advent of bioengineered alternative tissue, have provided numerous options to help with wound closure. Bioengineered alternative tissue includes allografts derived from neonatal foreskin, umbilical cord and amniotic membrane and acellular dermal matrix derived from numerous sources.

The US uses the most where as the other countries In Asia don’t fully utilise it due to cost issues.

**Smart technologies**

A systematic review by the IWGDF published in 2016 revealed some evidence to support the use of home monitoring foot skin temperature to identify abnormal values at increased risk for foot ulcer. Self-monitor
of foot temperature in combination with appropriate foot care may be effective at ulcers prevention.

**Summary**

Not every country has access to all these products. Where products are available the diagnosis may govern which are covered by reimbursement or insurance. An example is the US where a diagnosis of diabetes leads to access to advanced products and more highly-skilled practitioners. Furthermore treatment modalities vary across the world, depending on local guidelines and professional groups that manage the wound. This document hopes to create some equity on how patients are managed, to provide information that enables adoption of best practices, and where needed to stimulate development of standards of care and education.
Education

Wound management grows ever more sophisticated as our understanding of the fundamentals of wound formation, management, and prevention increases. Standards of care advance; products, technologies and processes that improve care and outcomes are developed and launched. Education, for health professionals and patients, is vital. Education is the first step in ulcer prevention and management. This section addresses areas of patient, health professional and societal education to drive better patient-directed prevention and practitioner led prevention and management.

Education is a long-term commitment for the learner and the educator requiring message(s) repeated consistently over time in different formats. People learn in different ways, which the educator must acknowledge and offer content that fits different learning styles. Furthermore, they must understand that the ability of the learner to see/hear the message, assimilate and reduce it to practice, varies by individual. Educational materials must account for these differences, understanding that many patients and family members may have basic educational attainment and poor language skills. Many patients, and indeed practitioners (Lavallée et al 2018), already have long-standing and firmly-held beliefs about the condition gleaned from sources which do not accord with medical opinion. For many, perhaps most patients, medical language is impenetrable.

This consensus focuses on three areas for education:

- Empower patients, families and carers
- The health system
- Social welfare

A useful mnemonic for education is EDUCATION defined as follows:

E: Empower
D: Develop/deserve what they need
U: Understand problems/risks
C: Care

The patient’s socio-economic status should be acknowledged, with the aim of maximising the role of the patient in reaching outcomes. Key areas are understanding the condition; the implications and how they may affect the patient; risk categories; understanding glycaemia and managing it well in diabetes; how to prevent a wound forming; the role of foot protection by offloading and adhering to it; and daily foot care inspection and monitoring; what to do if problems arise with the foot and how to contact the right practitioner; what to do once the wound has formed (how to dress it, how to bathe with it); increase the level of knowledge about therapies, treatments, prevention of complications and prognosis; understand the patient’s, family’s and carer’s role in managing the wound and adhering to the care plan – how to help and encourage the patient; how to explain to others about their condition. The patient should also be able to help the practitioner during consultations. Preliminary evidence from Malaysia suggests patient education is successful, in that those participating were a (Sharoni et al 2017).
Delivery

Delivery can take a number of forms, clinic leaflets, posters, group sessions, face-to-face by the practitioner, pharmacists (when patients collect prescriptions), and websites. Facebook and social media can be a problem with fake items and ‘crystal waving’ (Pokorná, A., Leaper, D). It is also worth noting and publicising international days such as Stop the Pressure (15 November 2018) and World Diabetes Day (WWD) (14 November 2018).

The health system

Consistent delivery of care across the health-care system depends first and foremost on educating the health professionals in best practices, which are underpinned by effective products, technologies and organisational support. However consistent understanding of standards of care does not always exist (McIntosh & Ousey 2008; Refs from definitions section). The current baseline understanding of managing PU and DFU should be established. Health professionals should recognise the problem, know what to do and know how to operate within the health service. They must understand how best to educate their patients. Where gaps are identified education should be provided and regularly updated. Health professional education must be informed and supported by guidelines on best practice developed in many countries and through a number of specialist national and international professional organisations. Where these guidelines are not already adopted, or require updating, health professionals should introduce relevant guidelines and education. The focus in many health systems is management of existing ulcers; a shift to prevention supported by education of both patients and health professionals would benefit for patients, health professionals, and health-care systems and importantly be cost-effective (Barshes et al 2017).

The UK National Minimal Skills Framework (Diabetes UK 2011) covers health professionals competencies required to manage foot diseases associated with diabetes. This is a good starting point for the basic competencies for DFU, including identifying risk status, basic foot care and advice, and managing a newly-presenting ulcer. It further details the higher level skill sets required for assessment of PAD, neuropathy, specialist education, advice on footwear, arranging surveillance based on risk status, tissue imaging management of Charcot foot and other skills.

NICE in the UK has also proposed a list of practitioner education topics for PU prevention (NICE 2014 PU prevention CG179). Education includes identifying patients at risk, recognising pressure damage, prevention, referral, conducting a risk assessment, repositioning, pressure redistribution devices, how to discuss prevention with patients and carers, and sources of help and advice.

A comprehensive set of topics for patient education that the practitioner should be able to communicate to a patient with diabetes at risk of foot disease, and which the patient should expect to be told, is proposed by the Saskatchewan Ministry of Health in Canada (Saskatchewan Ministry of Health 2016). The list, a good template for patient-focused education on self-management, suggests:

- Self-care and monitoring of diabetes
- The potential impact of diabetes on the feet
- Daily examination of feet and when to seek advice from a health professional. Indicators include any colour change; swelling; breaks in the skin; pain or numbness; if self-care and monitoring is not possible or difficult
- Implications of loss of protective sensation
- Possible consequences of neglecting the feet
- Methods to help self-examination/monitoring (for example, the use of mirrors if mobility is limited
- Hygiene (daily washing and careful drying)
- Skin care (moisturiser use)
- Nail care
- Dangers associated with inappropriate mechanical and chemical skin removal
- Footwear (the importance of well-fitting shoes
Education

- Injury prevention and the importance of not walking barefoot when reduced sensation is present
- Annual foot exam by trained professional to assess for neuropathy and vascular disease
- Prompt detection and management of any problems are important, and seeking help as soon as possible

Societal
The general public tend to have at best incomplete knowledge of medical matters, and at worst ‘knowledge’ gleaned from unreliable sources. The current media attention focused on multiple drug-resistant organisms is an example of how this can be addressed although compelling evidence showing wider understanding and behaviour change is yet to be seen. October is Breast Cancer Awareness month and this is widely known – for a disease that is known by all and feared in equal measure and for which people are motivated and mobilised to raise funds through charity events. However, few people know that September is PAD Awareness month. These messages show how societal education perhaps should be tackled. The messages should raise awareness, understanding and societal support for patients suffering from non-healing wounds. The public should be made aware not only of the causes of PU and DFU and how their choices affect the causes, but also the impact non-healing wounds have on quality of life, and life itself. A DFU for example is associated with increased risk of mortality (Walsh et al 2016). Vehicles for achieving greater awareness are NGOs, religious organisations, the media. The impact that chronic wounds have in the UK was discussed in Parliament in 2017. The awareness that triggered the debate was raised by publications demonstrating the financial and organisational impact of non-healing wounds. Perhaps this is a model for the future.
Development of consensus guidelines for chronic wounds is based on available information on the underlying disease, the pathophysiology of ulceration and tissue breakdown, the influence of pathophysiology on recalcitrance, conversion of a chronic non-healing ulcer into a healing wound that will close and remain closed, the causes of recurrence, the influence of individual treatments, the efficacy of standards of care, and nutrition. Consensus opinions consider the quality of available data by examining the methodological strength of published studies as well as consideration of real-world expert opinion based on experience. In so doing gaps are identified in the evidence base which are filled initially by expert opinion but should be strengthened by methodologically sound studies. A number of gaps were identified by the expert panel convened to develop this document.

Physiology of DFU and PU at the cellular level. A considerable body of evidence has been amassed to show how chronic wounds form and this is largely understood at the tissue level for PU and DFU (Jude et al 2001; Folestad et al 2015; Dekker et al 2016; Cunnion et al 2017; Caskey et al 2014; Mirza et al 2015; Rogers et al 1995; Lazaro et al 2016). The role of PAD is also largely understood. The changes in skin due to diabetes before and after ulceration are described (Weaving 2016) the impact of advanced glycation end products on inflammation has been described (Vlassara & Uribarri 2014) and a possible role for Staphylococcus aureus has been identified (Ramirez et al 2017). Some genetic associations are becoming clearer (Margolis et al 2017). A clearer understanding of the physiology of PU and DFU at the cellular level may help develop products targeted more effectively at the pathophysiology of these ulcers.

Nutrition in DFU: Nutrition is a key component in standards of care for chronic wounds but little is understood for DFU. The diabetic patient has metabolic challenges with glycaemic control and the full impact of the changes that happen in tissues of patients with diabetes that affect healing may not yet be fully elucidated.

Evidence to support advanced modalities for PU. Many wound management technologies have not been subjected to rigorous high-quality randomised clinical trials (RCT). Where trials and evaluations have been conducted, often they are methodologically poor. When data from these studies are analysed using health technology assessment methodology they are often found wanting, leaving interpretation of the clinical efficacy equivocal and supported by expert opinion. Patient care would be well-served by often expensive advanced technologies with claims for benefits having those benefits supported by high quality, methodologically and statistically rigorous RCTs.

This is a consensus document developed by an expert panel. The panel reached a consensus on differentiating between PU and DFU on the heel in particular and in so doing arrived at a series of recommendations that would ideally be implemented. However the panel recognised that the recommendations in their entirety may not fit every health-care system for a variety of reasons discussed in the document. These recommendations should therefore be used in line with local/national guidelines that are relevant to the reader’s own country/area. It should be regarded as a working document aimed to help health professionals make sense of a very challenging area.
8 Vowden P, Vowden K. Diabetic foot ulcer or pressure ulcer? That is the question. Diabetic Foot Canada 2016;4:26-29
Who to ask in your institution